ClinicalTrials.gg
CompletedNCT01815424Updated Apr 16, 2019Results posted

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis

A Phase 3 interventional study of placebo and CP-690,550 in Psoriasis, sponsored by Pfizer. Completed at 24 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.

Enrollment
8th of 19
266 · median 135
Started
2013
with 2 others
Phase 3
9 of 19
1 open now
Registered
12th of 19
by date
Lead sponsor
14 of 19
Pfizer

Among the 19 studies testing tofacitinib in Psoriasis, this one is the 8th largest by enrollment, is one of 3 that started in 2013, is one of 9 in phase 3, and was the 12th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tofacitinib in Psoriasis, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

03

Conditions studied

  • Psoriasis

Keywords

  • Tofacitinib
  • CP-690
  • 550
  • Xeljanz
  • Jak-Inhibitor
  • Oral Treatment
  • Psoriasis vulgaris
  • Pruritus
  • Itch
  • DLQI
  • moderate
  • severe
  • chronic
  • plaque psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have had a diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12 months prior to the first screening procedure.
  • Have a PASI score of 12 or greater AND a PGA score of 3 ("moderate") or 4 ("severe") at Baseline (Day 1).
  • Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment).

Exclusion criteria

Exclusion Criteria:

  • Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis, with the exception of nail psoriasis which is allowed.
  • Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium.
  • Subjects who cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA) for the study are excluded.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
266 participants (actual)

Study arms

  • Placebo comparator
    Placebo BID

    Drug: placebo

  • Experimental
    5mg BID CP-690,550

    Drug: CP-690,550

  • Experimental
    10mg BID CP-690,550

    Drug: CP-690,550

Interventions

  • Drugplacebo

    placebo BID for 16 weeks and then re-randomized into active groups

  • CP-690,550 5mg BID for 52 weeks

  • CP-690,550 10mg BID for 52 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" at Week 16

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

    Time frame: Week 16

  2. Percentage of Participants Achieving at Least a 75% Reduction in PASI (PASI75) at Week 16

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to Baseline.

    Time frame: Week 16

Secondary outcomes

  1. Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16

    Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

    Time frame: Baseline to Week 16

  2. Percentage of Participants Achieving at Least a 90% Reduction in PASI (PASI90) at Week 16

    The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90% reduction in PASI relative to Baseline.

    Time frame: Week 16

  3. Change From Baseline in DLQI Total Score at Week 16

    The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline to Week 16

  4. Percentage of Participants With PGA Score of "Clear" or "Almost Clear" at Week 4

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

    Time frame: Week 4

  5. Percentage of Participants Achieving PASI75 Response at Week 4

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.

    Time frame: Week 4

  6. Change From Baseline in DLQI Total Score at Week 4

    The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline to Week 4

  7. Percent Change From Baseline in Nail Psorasis Severity Index (NAPSI) at Week 16 in Participants With Nail Psoriasis at Baseline

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represent more severe psoriasis.

    Time frame: Baseline to Week 16

  8. Percentage of Participants Maintaining PGA Score of "Clear" or "Almost Clear" at Week 52 Among Participants Achieving PGA Response at Week 16

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among patients achieving PGA response at Week 16 is reported. This is a key secondary endpoint. Percentage of participants maintaining the response and the 95% confidence interval (CI) were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).

    Time frame: Week 16 to Week 52

  9. Percentage of Participants Maintaining PASI75 Response at Week 52 Among Participants Achieving PASI75 Response at Week 16

    The PASI quantifies severity of a participant's psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response=at least 75% reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among patients achieving PASI75 response at Week 16 is reported. This is a key secondary endpoint. Probability and the 95% CI were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).

    Time frame: Week 16 to Week 52

  10. Percentage of Participants Maintaining PASI90 Response at Week 52 Among Participants Achieving PASI90 at Week 16

    The PASI quantifies severity of a participant's psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response=at least 90% reduction in PASI relative to Baseline. Maintenance of PASI90 response at Week 52 among patients achieving PASI90 response at Week 16 is reported. This is a key secondary endpoint. Probability and the 95% CI were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).

    Time frame: Week 16 to Week 52

  11. Time to PGA Response up to Week 16

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if less than 50% of participants had PGA response by Week 16.

    Time frame: Baseline to Week 16

  12. Time to PASI75 Response up to Week 16

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if less than 50% of participants had PASI50 response by Week 16.

    Time frame: Baseline up to Week 16

  13. Time to PASI50 Response up to Week 16

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

    Time frame: Baseline up to Week 16

  14. Percentage of Participants With PGA Response of 'Clear' or 'Almost Clear' Over Time Through Week 52

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  15. Percentage of Participants in Each PGA Category Over Time Through Week 52

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  16. Percentage of Participants Achieving PASI75 Response Over Time Through Week 52

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  17. Actual PASI Scores Over Time Through Week 52

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, 52

  18. Change From Baseline in PASI Over Time Through Week 52

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  19. PASI Component Scores Over Time Through Week 52

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of BSA" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  20. Change From Baseline in PASI Component Scores Over Time Through Week 52

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of body surface area (BSA)" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  21. Percent Change From Baseline in PASI Scores Over Time Through Week 52

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  22. Actual BSA Over Time Through Week 52

    Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  23. Percent Change From Baseline in BSA Over Time Through Week 52

    Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

    Time frame: Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  24. Percentage of Participants With PASI50 Response Over Time Through Week 52

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. Percentage of participants with PASI50 response is reported.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  25. Percentage of Participants With PASI90 Response Over Time Through Week 52

    The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least 90% reduction in PASI relative to Baseline. Percentage of participants with PASI90 response up to Week 52 is reported.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  26. Percentage of Participants With PASI125 Over Time Through Week 52

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percentage of participants with PASI score of at least 125% of baseline PASI score are reported.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  27. Actual Nail Psoriasis Severity Index (NAPSI) Score Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.

    Time frame: Baseline and Weeks 8, 16, 20, 32, 40, and 52

  28. Change From Baseline in NAPSI Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail was divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.

    Time frame: Baseline and weeks 8, 16, 20, 32, 40, and 52

  29. Number of Affected Nails in Participants With Nail Psoriasis at Baseline Over Time Through Week 52

    Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported. The total number of affected FINGER nails was reported.

    Time frame: Baseline and Weeks 8, 16, 20, 32, 40, and 52

  30. Percent Change From Baseline in NAPSI Over Time Through Week 52

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.

    Time frame: Baseline and weeks 8, 16, 20, 32, 40, and 52

  31. Percentage of Participants With NAPSI75 Response Over Time Through Week 52

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported.

    Time frame: Weeks 8, 16, 20, 32, 40, and 52

  32. Percentage of Participants With NAPSI100 Response Over Time Through Week 52

    The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported.

    Time frame: Weeks 8, 16, 20, 32, 40, and 52

  33. Actual Itch Severity Item (ISI) Score Over Time Through Week 52

    ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  34. Change From Baseline in ISI Score Over Time Through Week 52

    ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  35. Actual Dermatology Life Quality Index (DLQI) Score Over Time Through Week 52

    The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  36. Change From Baseline in DLQI Score Over Time Through Week 52

    The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  37. Percentage of Participants With Patient Global Assessment (PtGA) Response of "Clear" or "Almost Clear" Over Time Through Week 52

    The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear \[no psoriasis\]; 1=almost clear; 2=mild; 3=moderate; 4=severe). the percentage of participants with scores of 0 (clear) and 1 (almost clear) are reported.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52

  38. Euro Quality of Life 5 Dimensions (EQ-5D) - Utility Score Over Time Through Week 52

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a worse health state.

    Time frame: Baseline, Weeks 16, 32, 40, 52

  39. Change From Baseline in EQ-5D - Utility Score Over Time Through Week 52

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a worse health state.

    Time frame: Baseline and weeks 16, 32, 40, and 52

  40. Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) Over Time Through Week 52

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline and Weeks 16, 32, 40, and 52

  41. Change From Baseline in EQ-5D - Visual Analog Scale (VAS) Over Time Through Week 52

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline and weeks 16, 32, 40, and 52

Other outcomes

  1. Treatment-Emergent All Causalities Adverse Events (AEs) During Week 0-16

    An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.

    Time frame: Baseline to Week 16

  2. Treatment-Emergent All Causalities Adverse Events (AEs) During Week 0-52

    An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.

    Time frame: Baseline to Week 52

  3. Number of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-16

    Study drugs were to be discontinued and the participant withdrawn for: 2 sequential absolute neutrophil counts (ANC) \<1.0 X 10\^9/L (1000/mm\^3); 2 sequential absolute lymphocyte counts \<0.5 X 10\^9/L; 2 sequential hemoglobin values \<9.0 g/dL and/or decreases of \>30% from baseline value; 2 sequential platelet counts \<75 X 10\^9/L; 2 sequential AST or ALT elevations ≥3X ULN with at least 1 total bilirubin value ≥2X ULN (reason #1); 2 sequential AST or ALT elevations ≥5X ULN regardless of total bilirubin or accompanying signs or symptoms (reason #2); 2 sequential increases in serum creatinine \>50% and an increase in serum creatinine \>0.5 mg/dL over the average of screening and baseline values; 2 sequential CK elevations \>10X ULN.

    Time frame: Baseline to Week 16

  4. Number of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-52

    Study drugs were to be discontinued and the participant withdrawn for: 2 sequential absolute neutrophil counts (ANC) \<1.0 X 10\^9/L (1000/mm\^3); 2 sequential absolute lymphocyte counts \<0.5 X 10\^9/L; 2 sequential hemoglobin values \<9.0 g/dL and/or decreases of \>30% from baseline value; 2 sequential platelet counts \<75 X 10\^9/L; 2 sequential AST or ALT elevations ≥3X ULN with at least 1 total bilirubin value ≥2X ULN (reason #1); 2 sequential AST or ALT elevations ≥5X ULN regardless of total bilirubin or accompanying signs or symptoms (reason #2); 2 sequential increases in serum creatinine \>50% and an increase in serum creatinine \>0.5 mg/dL over the average of screening and baseline values; 2 sequential CK elevations \>10X ULN.

    Time frame: Baseline up to Week 52

  5. Number of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-16

    Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: pulse rate less than (\<)40 or greater than (\>)120 beats per minute (bpm), heart rate less than (\<)40 or greater than (\>)120 bpm; sitting systolic blood pressure (SBP) of greater than or equal to (\>=)30 millimeters of mercury (mmHg) change from baseline or sitting SBP \<90 mmHg, sitting diastolic blood pressure (DBP) \>=20 mmHg change from baseline or sitting DBP \<50 mmHg.

    Time frame: Baseline to Week 16

  6. Number of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-52

    Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: pulse rate less than (\<)40 or greater than (\>)120 beats per minute (bpm), heart rate less than (\<)40 or greater than (\>)120 bpm; sitting systolic blood pressure (SBP) of greater than or equal to (\>=)30 millimeters of mercury (mmHg) change from baseline or sitting SBP \<90 mmHg, sitting diastolic blood pressure (DBP) \>=20 mmHg change from baseline or sitting DBP \<50 mmHg.

    Time frame: Baseline to Week 52

  7. Incidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-16

    CV event categories included: cerebrovascular accident (CVA), coronary revascularization procedure (percutaneous transluminal coronary angioplasty \[PTCA\], percutaneous coronary intervention \[PCI\], coronary bypass grafting \[CABG\], heart failure, major adverse cardiac events (MACE), myocardial infarction (MI), new ischemic heart disease, peripheral vascular disease (first diagnosis). MACE included any MI, CVA (stroke or transient ischemic attack), or CV death.

    Time frame: Baseline to Week 16

  8. Incidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-52

    CV event categories included: cerebrovascular accident (CVA), coronary revascularization procedure (percutaneous transluminal coronary angioplasty \[PTCA\], percutaneous coronary intervention \[PCI\], coronary bypass grafting \[CABG\], heart failure, major adverse cardiac events (MACE), myocardial infarction (MI), new ischemic heart disease, peripheral vascular disease (first diagnosis). MACE included any MI, CVA (stroke or transient ischemic attack), or CV death.

    Time frame: Baseline up to Week 52

  9. Number of Participants With Adjudicated Malignancy Events Reported During Week 0-16

    As part of AE monitoring, potential malignancy events were adjudicated and centrally reviewed by a safety committee.

    Time frame: Baseline to Week 16

  10. Number of Participants With Adjudicated Malignancy Events Reported During Week 0-52

    As part of AE monitoring, potential malignancy events were adjudicated and centrally reviewed by a safety committee.

    Time frame: Baseline to Week 52

07

Results

Posted Mar 5, 2019

Participant flow

Week 0 to 16
Participant flow — Week 0 to 16
MilestoneTofacitinib 10 mgTofacitinib 5 mgPlaceboPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Started90888800
Completed83847700
Not completed741100
Withdrew: Adverse event13300
Withdrew: Does not meet entrance criteria20000
Withdrew: Lost to follow-up01000
Withdrew: Withdrawal by subject00100
Withdrew: Other10300
Withdrew: Protocol violation10000
Withdrew: Insufficient clinical response20400
Week 16 to 52
Participant flow — Week 16 to 52
MilestoneTofacitinib 10 mgTofacitinib 5 mgPlaceboPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Started838403839
Completed817903536
Not completed25033
Withdrew: Other01000
Withdrew: Adverse event00001
Withdrew: Insufficient clinical response10011
Withdrew: Lost to follow-up02021
Withdrew: Withdrawal by subject12000

Outcome measures

PrimaryPercentage of Participants With Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" at Week 16

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" at Week 16
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo
Percentage of Participants With Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" at Week 1675.5652.2719.32
Statistical analysis
  • Tofacitinib 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.05 (2-sided).) · Odds ratio (or): 14.52 · 95% CI 6.03 to 32.77
  • Tofacitinib 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.05 (2-sided).) · Odds ratio (or): 5.27 · 95% CI 2.46 to 11.86
PrimaryPercentage of Participants Achieving at Least a 75% Reduction in PASI (PASI75) at Week 16

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to Baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 75% Reduction in PASI (PASI75) at Week 16
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo
Percentage of Participants Achieving at Least a 75% Reduction in PASI (PASI75) at Week 1681.1154.5512.50
Statistical analysis
  • Tofacitinib 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.05 (2-sided).) · Odds ratio (or): 41.71 · 95% CI 14.84 to 151.11
  • Tofacitinib 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.05 (2-sided).) · Odds ratio (or): 9.97 · 95% CI 4.06 to 25.17
SecondaryPercent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16

Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16
percent changeTofacitinib 10 mgTofacitinib 5 mgPlacebo
Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16-73.81 ± 5.903-54.39 ± 5.838-2.27 ± 6.061
Statistical analysis
  • Tofacitinib 10 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance of 0.025 (2-sided).) · Least square mean difference: -71.54 · 95% CI -88.20 to -54.87
  • Tofacitinib 5 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance level of 0.025 (2-sided).) · Least square mean difference: -52.12 · 95% CI -68.70 to -35.55
SecondaryPercentage of Participants Achieving at Least a 90% Reduction in PASI (PASI90) at Week 16

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90% reduction in PASI relative to Baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 90% Reduction in PASI (PASI90) at Week 16
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo
Percentage of Participants Achieving at Least a 90% Reduction in PASI (PASI90) at Week 1660.00 ± 5.90335.23 ± 5.8383.41 ± 6.061
Statistical analysis
  • Tofacitinib 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Odds ratio (or): 70.31 · 95% CI 13.38 to 267.15
  • Tofacitinib 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).) · Odds ratio (or): 16.44 · 95% CI 4.31 to 79.62
SecondaryChange From Baseline in DLQI Total Score at Week 16

The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · scores on a scale
Change From Baseline in DLQI Total Score at Week 16
scores on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo
Change From Baseline in DLQI Total Score at Week 16-9.10 ± 0.635-7.03 ± 0.627-1.57 ± 0.655
Statistical analysis
  • Tofacitinib 10 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance of 0.025 (2-sided).) · Least square mean difference: -7.52 · 95% CI -9.32 to 5.72
  • Tofacitinib 5 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance of 0.025 (2-sided).) · Least square mean difference: -5.45 · 95% CI -7.24 to -3.67
SecondaryPercentage of Participants With PGA Score of "Clear" or "Almost Clear" at Week 4

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With PGA Score of "Clear" or "Almost Clear" at Week 4
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo
Percentage of Participants With PGA Score of "Clear" or "Almost Clear" at Week 437.78 ± 0.49719.32 ± 0.4931.14 ± 0.504
Statistical analysis
  • Tofacitinib 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.025 (2-sided).) · Odds ratio (or): 114.40 · 95% CI 8.95 to 2657.62
  • Tofacitinib 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.025 (2-sided).) · Odds ratio (or): 35.37 · 95% CI 3.47 to 1084.02
SecondaryPercentage of Participants Achieving PASI75 Response at Week 4

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI75 Response at Week 4
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo
Percentage of Participants Achieving PASI75 Response at Week 424.444.550.00
Statistical analysis
  • Tofacitinib 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.025 (2-sided).)OR and 95% CI not available due to 0% frequency in placebo group.
  • Tofacitinib 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0386 (Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.025 (2-sided).)OR and 95% CI not available due to 0% frequency in placebo group.
SecondaryChange From Baseline in DLQI Total Score at Week 4

The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · scores on a scale
Change From Baseline in DLQI Total Score at Week 4
scores on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo
Change From Baseline in DLQI Total Score at Week 4-6.03 ± 0.497-5.14 ± 0.493-0.94 ± 0.504
Statistical analysis
  • Tofacitinib 10 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance of 0.025 (2-sided).) · Least square mean difference: -5.09 · 95% CI -6.49 to -3.70
  • Tofacitinib 5 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance of 0.025 (2-sided).) · Least square mean difference: -4.20 · 95% CI -5.59 to -2.81
SecondaryPercent Change From Baseline in Nail Psorasis Severity Index (NAPSI) at Week 16 in Participants With Nail Psoriasis at Baseline

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represent more severe psoriasis.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Nail Psorasis Severity Index (NAPSI) at Week 16 in Participants With Nail Psoriasis at Baseline
percent changeTofacitinib 10 mgTofacitinib 5 mgPlacebo
Percent Change From Baseline in Nail Psorasis Severity Index (NAPSI) at Week 16 in Participants With Nail Psoriasis at Baseline-33.32 ± 10.518-14.98 ± 10.5667.91 ± 12.025
Statistical analysis
  • Tofacitinib 10 mg vs Placebo · Mixed Models Analysis · p = 0.0113 (Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance level of 0.025 (2-sided).) · Least square mean of difference: -41.23 · 95% CI -72.91 to -9.54
  • Tofacitinib 5 mg vs Placebo · Mixed Models Analysis · p = 0.1558 (Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance level of 0.025 (2-sided).) · Least square mean of difference: -22.89 · 95% CI -54.64 to 8.86
SecondaryPercentage of Participants Maintaining PGA Score of "Clear" or "Almost Clear" at Week 52 Among Participants Achieving PGA Response at Week 16

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among patients achieving PGA response at Week 16 is reported. This is a key secondary endpoint. Percentage of participants maintaining the response and the 95% confidence interval (CI) were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).

Time frame:
Week 16 to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining PGA Score of "Clear" or "Almost Clear" at Week 52 Among Participants Achieving PGA Response at Week 16
percentage of participantsTofacitinib 10 mgTofacitinib 5 mg
Percentage of Participants Maintaining PGA Score of "Clear" or "Almost Clear" at Week 52 Among Participants Achieving PGA Response at Week 1675.00 ± 0.49773.63 ± 0.493
SecondaryPercentage of Participants Maintaining PASI75 Response at Week 52 Among Participants Achieving PASI75 Response at Week 16

The PASI quantifies severity of a participant's psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response=at least 75% reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among patients achieving PASI75 response at Week 16 is reported. This is a key secondary endpoint. Probability and the 95% CI were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).

Time frame:
Week 16 to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining PASI75 Response at Week 52 Among Participants Achieving PASI75 Response at Week 16
percentage of participantsTofacitinib 10 mgTofacitinib 5 mg
Percentage of Participants Maintaining PASI75 Response at Week 52 Among Participants Achieving PASI75 Response at Week 1684.93 ± 0.49776.82 ± 0.493
SecondaryPercentage of Participants Maintaining PASI90 Response at Week 52 Among Participants Achieving PASI90 at Week 16

The PASI quantifies severity of a participant's psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response=at least 90% reduction in PASI relative to Baseline. Maintenance of PASI90 response at Week 52 among patients achieving PASI90 response at Week 16 is reported. This is a key secondary endpoint. Probability and the 95% CI were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).

Time frame:
Week 16 to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining PASI90 Response at Week 52 Among Participants Achieving PASI90 at Week 16
percentage of participantsTofacitinib 10 mgTofacitinib 5 mg
Percentage of Participants Maintaining PASI90 Response at Week 52 Among Participants Achieving PASI90 at Week 1674.07 ± 0.49770.45 ± 0.493
SecondaryTime to PGA Response up to Week 16

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if less than 50% of participants had PGA response by Week 16.

Time frame:
Baseline to Week 16
Reported as:
Median · weeks
Time to PGA Response up to Week 16
weeksTofacitinib 10 mgTofacitinib 5 mgPlacebo
Time to PGA Response up to Week 168.0 (4.0 to 8.0)14.0 (12.0 to NA)NA (NA to NA)
SecondaryTime to PASI75 Response up to Week 16

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if less than 50% of participants had PASI50 response by Week 16.

Time frame:
Baseline up to Week 16
Reported as:
Median · weeks
Time to PASI75 Response up to Week 16
weeksTofacitinib 10 mgTofacitinib 5 mgPlacebo
Time to PASI75 Response up to Week 168.0 (8.0 to 12.0)16.0 (12.0 to NA)NA (NA to NA)
SecondaryTime to PASI50 Response up to Week 16

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.

Time frame:
Baseline up to Week 16
Reported as:
Median · weeks
Time to PASI50 Response up to Week 16
weeksTofacitinib 10 mgTofacitinib 5 mgPlacebo
Time to PASI50 Response up to Week 164.0 (4.0 to 8.0)8.0 (8.0 to 12.0)NA (NA to NA)
SecondaryPercentage of Participants With PGA Response of 'Clear' or 'Almost Clear' Over Time Through Week 52

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With PGA Response of 'Clear' or 'Almost Clear' Over Time Through Week 52
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 23.33 (0.00 to 7.04)2.27 (0.00 to 5.39)0.00 (NA to NA)0.00 (NA to NA)
Week 437.78 (27.76 to 47.79)19.32 (11.07 to 27.57)2.27 (0.00 to 6.68)0.00 (NA to NA)
Week 857.78 (47.57 to 67.98)38.64 (28.46 to 48.81)11.36 (1.99 to 20.74)0.00 (NA to NA)
Week 1274.44 (65.43 to 83.46)50.00 (39.55 to 60.45)25.00 (12.21 to 37.79)6.82 (0.00 to 14.27)
Week 1675.56 (66.68 to 84.43)52.27 (41.84 to 62.71)29.55 (16.06 to 43.03)9.09 (0.60 to 17.59)
Week 2075.56 (66.68 to 84.43)54.55 (44.14 to 64.95)59.09 (44.56 to 73.62)47.73 (32.97 to 62.49)
Week 3273.33 (64.20 to 82.47)53.41 (42.99 to 63.83)68.18 (54.42 to 81.94)52.27 (37.51 to 67.03)
Week 4072.22 (62.97 to 81.48)55.68 (45.30 to 66.06)65.91 (51.90 to 79.92)54.55 (39.83 to 69.26)
Week 5267.78 (58.12 to 77.43)54.55 (44.14 to 64.95)59.09 (44.56 to 73.62)50.00 (35.23 to 64.77)
SecondaryPercentage of Participants in Each PGA Category Over Time Through Week 52

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants in Each PGA Category Over Time Through Week 52
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Baseline: Clear (n=90,88,44,44)0 (95.67 to 100.0)0 (83.16 to 99.45)00
Baseline: Almost Clear (n=90,88,44,44)0000
Baseline: Mild (n=90,88,44,44)0000
Baseline: Moderate (n=90,88,44,44)85.687.581.870.5
Baseline: Severe (n=90,88,44,44)14.412.518.229.5
Week 2: Clear (n=88,86,44,42)0000
Week 2: Almost Clear (n=88,86,44,42)3.42.300
Week 2: Mild (n=88,86,44,42)47.736.011.44.8
Week 2: Moderate (n=88,86,44,42)40.955.875.071.4
Week 2: Severe (n=88,86,44,42)8.05.813.623.8
Week 4: Clear (n=87,88,43,42)2.31.100
Week 4: Almost Clear (n=87,88,43,42)36.818.22.30
Week 4: Mild (n=87,88,43,42)29.939.823.314.3
Week 4: Moderate (n=87,88,43,42)27.636.453.569.0
Week 4: Severe (n=87,88,43,42)3.44.520.916.7
Week 8: Clear (n=85,88,40,39)23.53.400
Week 8: Almost Clear (n=85,88,40,39)37.635.212.50
Week 8: Mild (n=85,88,40,39)20.028.430.025.6
Week 8: Moderate (n=85,88,40,39)17.630.742.561.5
Week 8: Severe (n=85,88,40,39)1.22.315.012.8
Week 12: Clear (n=84,88,40,39)34.512.500
Week 12: Almost Clear (n=84,88,40,39)45.237.527.57.7
Week 12: Mild (n=84,88,40,39)11.927.330.030.8
Week 12: Moderate (n=84,88,40,39)6.022.737.551.3
Week 12: Severe (n=84,88,40,39)2.405.010.3
Week 16: Clear (n=84,84,38,39)42.916.75.30
Week 16: Almost Clear (n=84,84,38,39)38.138.128.910.3
Week 16: Mild (n=84,84,38,39)9.521.426.330.8
Week 16: Moderate (n=84,84,38,39)9.523.834.251.3
Week 16: Severe (n=84,84,38,39)005.37.7
Week 20: Clear (n=84,84,38,39)50.025.015.82.6
Week 20: Almost Clear (n=84,84,38,39)31.032.152.651.3
Week 20: Mild (n=84,84,38,39)11.929.818.438.5
Week 20: Moderate (n=84,84,38,39)7.113.113.27.7
Week 20: Severe (n=84,84,38,39)0000
Week 32: Clear (n=83,83,38,37)51.831.344.729.7
Week 32: Almost Clear (n=83,83,38,37)27.725.334.232.4
Week 32: Mild (n=83,83,38,37)13.326.518.432.4
Week 32: Moderate (n=83,83,38,37)7.216.92.65.4
Week 32: Severe (n=83,83,38,37)0000
Week 40: Clear (n=81,81,37,36)53.129.648.636.1
Week 40: Almost Clear (n=81,81,37,36)27.230.929.730.6
Week 40: Mild (n=81,81,37,36)13.625.913.519.4
Week 40: Moderate (n=81,81,37,36)6.213.68.113.9
Week 40: Severe (n=81,81,37,36)0000
Week 52: Clear (n=80,78,36,36)45.025.650.030.6
Week 52: Almost Clear (n=80,78,36,36)31.335.922.230.6
Week 52: Mild (n=80,78,36,36)16.319.216.730.6
Week 52: Moderate (n=80,78,36,36)7.517.911.18.3
Week 52: Severe (n=80,78,36,36)01.300
SecondaryPercentage of Participants Achieving PASI75 Response Over Time Through Week 52

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI75 Response Over Time Through Week 52
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 21.11 (0.00 to 3.28)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)
Week 424.44 (15.57 to 33.32)4.55 (0.19 to 8.90)0.00 (NA to NA)0.00 (NA to NA)
Week 851.11 (40.78 to 61.44)31.82 (22.09 to 41.55)2.27 (0.00 to 6.68)2.27 (0.00 to 6.68)
Week 1272.22 (62.97 to 81.48)47.73 (37.29 to 58.16)11.36 (1.99 to 20.74)2.27 (0.00 to 6.68)
Week 1681.11 (73.02 to 89.20)54.55 (44.14 to 64.95)20.45 (8.54 to 32.37)4.55 (0.00 to 10.70)
Week 2083.33 (75.63 to 91.03)54.55 (44.14 to 64.95)52.27 (37.51 to 67.03)27.27 (14.11 to 40.43)
Week 3281.11 (73.02 to 89.20)59.09 (48.82 to 69.36)75.00 (62.21 to 87.79)65.91 (51.90 to 79.92)
Week 4080.00 (71.74 to 88.26)56.82 (46.47 to 67.17)68.18 (54.42 to 81.94)65.91 (51.90 to 79.92)
Week 5276.67 (67.93 to 85.40)59.09 (48.82 to 69.36)63.64 (49.42 to 77.85)59.09 (44.56 to 73.62)
SecondaryActual PASI Scores Over Time Through Week 52

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, 52
Reported as:
Mean · percentage of participants
Actual PASI Scores Over Time Through Week 52
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Baseline (n=90,88,44,44)25.34 ± 9.10625.32 ± 10.18525.62 ± 10.42926.51 ± 8.525
Week 2 (n=88,86,44,42)19.03 ± 9.39221.23 ± 9.97925.72 ± 10.58226.34 ± 9.456
Week 4 (n=87,88,43,42)13.81 ± 9.82617.41 ± 10.56524.81 ± 12.08124.65 ± 9.433
Week 8 (n=85,88,40,39)8.18 ± 9.07512.56 ± 10.62321.38 ± 11.68922.46 ± 8.966
Week 12 (n=84,88,40,39)4.56 ± 6.97910.10 ± 9.85817.83 ± 10.50321.35 ± 9.477
Week 16 (n=84,84,38,39)3.48 ± 6.7228.42 ± 9.80015.27 ± 11.44120.64 ± 9.738
Week 20 (84,84,38,39)2.75 ± 5.6107.13 ± 8.2806.52 ± 6.51210.43 ± 7.612
Week 32 (n=83,83,38,37)2.15 ± 3.8106.23 ± 7.8173.09 ± 5.4344.82 ± 5.517
Week 40 (n=81,81,37,36)2.04 ± 3.5535.74 ± 6.4152.79 ± 4.4583.74 ± 4.540
Week 52 (n=80,78,36,36)2.82 ± 4.6746.00 ± 7.3133.11 ± 5.0274.69 ± 4.607
SecondaryChange From Baseline in PASI Over Time Through Week 52

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Mean · units on a scale
Change From Baseline in PASI Over Time Through Week 52
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 2 (n=88,86,44,42)-6.40 ± 6.724-4.26 ± 5.2310.10 ± 4.715-0.04 ± 3.676
Week 4 (n=87,88,43,42)-11.74 ± 8.528-7.91 ± 7.053-0.76 ± 7.423-1.72 ± 3.799
Week 8 (n=85,88,40,39)-17.25 ± 10.244-12.76 ± 10.033-4.25 ± 8.996-4.51 ± 6.130
Week 12 (n=84,88,40,39)-20.98 ± 9.612-15.22 ± 11.214-7.71 ± 10.717-5.62 ± 7.169
Week 16 (n=84,84,38,39)-22.07 ± 10.127-17.12 ± 11.711-10.03 ± 12.976-6.33 ± 8.973
Week 20 (n=84,84,38,39)-22.79 ± 9.675-18.42 ± 10.955-18.79 ± 12.428-16.54 ± 8.732
Week 32 (n=83,83,38,37)-23.45 ± 9.369-19.45 ± 10.312-22.22 ± 11.550-21.86 ± 9.283
Week 40 (n=81,81,37,36)-23.47 ± 9.702-20.11 ± 10.292-22.80 ± 11.268-22.94 ± 9.512
Week 52 (n=80,78,36,36)-22.71 ± 10.655-20.04 ± 10.819-22.54 ± 12.368-22.00 ± 9.429
SecondaryPASI Component Scores Over Time Through Week 52

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of BSA" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Mean · units on a scale
PASI Component Scores Over Time Through Week 52
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Baseline: Erythema (Head/Neck) n=90,88,44,442.31 ± 0.8302.18 ± 0.9772.18 ± 1.0182.39 ± 0.868
Week 2: Erythema (Head/Neck) n=88,86,44,421.74 ± 0.9031.77 ± 1.0372.05 ± 1.0332.50 ± 0.834
Week 4: Erythema (Head/Neck) n=87,88,43,421.37 ± 0.9781.44 ± 1.0151.91 ± 1.0652.24 ± 0.726
Week 8: Erythema (Head/Neck) n=85,88,40,390.93 ± 0.9971.14 ± 1.0521.93 ± 1.1412.05 ± 1.075
Week 12: Erythema (Head/Neck) n=84,88,40,390.68 ± 0.8670.94 ± 1.0651.75 ± 1.1711.97 ± 1.038
Week 16: Erythema (Head/Neck) n=84,84,38,390.58 ± 0.8390.82 ± 1.0321.47 ± 1.1561.82 ± 1.073
Week 20: Erythema (Head/Neck) n=84,84,38,390.50 ± 0.7840.82 ± 0.9710.76 ± 0.8831.08 ± 0.839
Week 32: Erythema (Head/Neck) n=83,83,38,370.58 ± 0.8850.73 ± 0.9890.45 ± 0.8600.84 ± 1.041
Week 40: Erythema (Head/Neck) n=81,81,37,360.51 ± 0.8820.74 ± 0.9460.43 ± 0.7280.64 ± 0.899
Week 52: Erythema (Head/Neck) n=80,78,36,360.58 ± 0.9250.72 ± 0.9660.47 ± 0.7740.78 ± 0.929
Baseline: Erythema (Upper Limbs) n=90,88,44,442.70 ± 0.6942.78 ± 0.6862.66 ± 0.8052.73 ± 0.624
Week 2: Erythema (Upper Limbs) n=88,86,44,422.06 ± 0.7932.28 ± 0.7922.68 ± 0.8292.90 ± 0.692
Week 4: Erythema (Upper Limbs) n=87,88,43,421.61 ± 0.8261.88 ± 0.9202.53 ± 0.9602.71 ± 0.673
Week 8: Erythema (Upper Limbs) n=85,88,40,391.05 ± 0.9371.47 ± 0.9822.35 ± 1.0752.51 ± 0.823
Week 12: Erythema (Upper Limbs) n=84,88,40,390.60 ± 0.7781.17 ± 1.0742.13 ± 1.0672.36 ± 0.873
Week 16: Erythema (Upper Limbs) n=84,84,38,390.51 ± 0.7840.99 ± 1.0241.71 ± 1.1372.33 ± 0.927
Week 20: Erythema (Upper Limbs) n=84,84,38,390.40 ± 0.7930.93 ± 0.9670.97 ± 0.7881.38 ± 0.877
Week 32: Erythema (Upper Limbs) n=83,83,38,370.40 ± 0.6970.96 ± 1.0870.55 ± 0.7600.86 ± 1.004
Week 40: Erythema (Upper Limbs) n=81,81,37,360.44 ± 0.7910.93 ± 1.0340.59 ± 0.9270.78 ± 0.866
Week 52: Erythema (Upper Limbs) n=80,78,36,360.56 ± 0.9390.95 ± 1.0310.69 ± 0.9800.89 ± 1.063
Baseline: Erythema (Trunk) n=90,88,44,442.86 ± 0.6962.81 ± 0.6582.86 ± 0.5102.93 ± 0.625
Week 2: Erythema (Trunk) n=88,86,44,422.28 ± 0.8302.44 ± 0.7762.84 ± 0.5683.05 ± 0.697
Week 4: Erythema (Trunk) n=87,88,43,421.82 ± 0.9222.05 ± 0.8832.72 ± 0.7342.83 ± 0.660
Week 8: Erythema (Trunk) n=85,88,40,391.20 ± 1.0561.65 ± 1.0062.50 ± 0.9872.64 ± 0.778
Week 12: Erythema (Trunk) n=84,88,40,390.81 ± 1.0241.44 ± 1.1332.20 ± 1.1372.54 ± 0.790
Week 16: Erythema (Trunk) n=84,84,38,390.63 ± 0.9291.21 ± 1.1731.87 ± 1.2342.64 ± 0.811
Week 20: Erythema (Trunk) n=84,84,38,390.62 ± 1.0051.12 ± 1.0801.08 ± 0.9971.31 ± 0.800
Week 32: Erythema (Trunk) n=83,83,38,370.58 ± 0.9521.02 ± 1.1370.53 ± 0.8930.70 ± 0.968
Week 40: Erythema (Trunk) n=81,81,37,360.48 ± 0.8230.96 ± 1.0780.43 ± 0.8350.67 ± 0.862
Week 52: Erythema (Trunk) n=80,78,36,360.59 ± 0.9240.99 ± 1.0990.64 ± 1.0730.92 ± 0.937
Baseline: Erythema (Lower Limbs) n=90,88,44,443.03 ± 0.6782.98 ± 0.6603.05 ± 0.7463.16 ± 0.608
Week 2: Erythema (Lower Limbs) n=88,86,44,422.53 ± 0.8702.60 ± 0.8303.05 ± 0.7763.24 ± 0.576
Week 4: Erythema (Lower Limbs) n=87,88,43,421.97 ± 0.9462.23 ± 0.8542.93 ± 0.8563.07 ± 0.677
Week 8: Erythema (Lower Limbs) n=85,88,40,391.33 ± 1.0511.78 ± 1.0772.70 ± 0.9392.92 ± 0.739
Week 12: Erythema (Lower Limbs) n=84,88,40,390.79 ± 0.8651.53 ± 1.0822.48 ± 1.0122.82 ± 0.756
Week 16: Erythema (Lower Limbs) n=84,84,38,390.67 ± 0.8831.44 ± 1.1552.13 ± 1.1662.77 ± 0.810
Week 20: Erythema (Lower Limbs) n=84,84,38,390.54 ± 0.8701.26 ± 1.0431.16 ± 0.9451.77 ± 0.842
Week 32: Erythema (Lower Limbs) n=83,83,38,370.47 ± 0.8601.13 ± 1.1970.66 ± 0.9091.11 ± 1.100
Week 40: Erythema (Lower Limbs) n=81,81,37,360.52 ± 0.9631.14 ± 1.1590.70 ± 0.9680.81 ± 0.889
Week 52: Erythema (Lower Limbs) n=80,78,36,360.70 ± 1.0241.24 ± 1.2810.78 ± 1.1980.94 ± 1.068
Baseline: Induration (Head/Neck) n=90,88,44,442.23 ± 0.9371.94 ± 0.9982.07 ± 1.0652.20 ± 0.930
Week 2: Induration (Head/Neck) n=88,86,44,421.63 ± 0.9981.67 ± 1.0112.00 ± 1.1002.19 ± 0.943
Week 4: Induration (Head/Neck) n=87,88,43,421.16 ± 1.0221.35 ± 1.0731.74 ± 1.0712.10 ± 0.932
Week 8: Induration (Head/Neck) n=85,88,40,390.84 ± 1.0101.08 ± 1.0741.55 ± 0.9591.92 ± 1.010
Week 12: Induration (Head/Neck) n=84,88,40,390.63 ± 0.8470.86 ± 1.0081.40 ± 0.9001.72 ± 0.972
Week 16: Induration (Head/Neck) n=84,84,38,390.51 ± 0.7360.73 ± 0.9741.29 ± 0.9841.56 ± 0.995
Week 20: Induration (Head/Neck) n=84,84,38,390.40 ± 0.6420.67 ± 0.9100.58 ± 0.6830.90 ± 0.718
Week 32: Induration (Head/Neck) n=83,83,38,370.49 ± 0.7550.57 ± 0.8140.32 ± 0.7020.62 ± 0.794
Week 40: Induration (Head/Neck) n=81,81,37,360.44 ± 0.7420.60 ± 0.8010.35 ± 0.6330.53 ± 0.810
Week 52: Induration (Head/Neck) n=80,78,36,360.53 ± 0.8710.60 ± 0.8880.44 ± 0.7350.61 ± 0.871
Baseline: Induration (Upper Limbs) n=90,88,44,442.71 ± 0.7382.59 ± 0.7832.57 ± 0.9252.77 ± 0.677
Week 2: Induration (Upper Limbs) n=88,86,44,422.02 ± 0.8842.16 ± 0.9192.52 ± 0.8762.74 ± 0.798
Week 4: Induration (Upper Limbs) n=87,88,43,421.54 ± 1.0541.82 ± 1.0122.35 ± 1.0212.62 ± 0.795
Week 8: Induration (Upper Limbs) n=85,88,40,391.01 ± 1.0291.40 ± 1.0782.03 ± 1.0502.36 ± 0.903
Week 12: Induration (Upper Limbs) n=84,88,40,390.55 ± 0.8131.13 ± 1.0811.78 ± 1.0002.23 ± 0.842
Week 16: Induration (Upper Limbs) n=84,84,38,390.39 ± 0.7611.05 ± 1.1081.55 ± 1.0832.08 ± 0.870
Week 20: Induration (Upper Limbs) n=84,84,38,390.37 ± 0.8180.90 ± 1.0130.89 ± 0.9241.18 ± 0.823
Week 32: Induration (Upper Limbs) n=83,83,38,370.42 ± 0.7980.96 ± 1.0640.58 ± 0.9190.78 ± 0.917
Week 40: Induration (Upper Limbs) n=81,81,37,360.47 ± 0.8670.94 ± 1.0410.49 ± 0.7680.75 ± 0.841
Week 52: Induration (Upper Limbs) n=80,78,36,360.53 ± 0.8860.90 ± 0.9880.58 ± 0.8740.81 ± 0.951
Baseline: Induration (Trunk) n=90,88,44,442.90 ± 0.6192.74 ± 0.7032.91 ± 0.7722.93 ± 0.695
Week 2: Induration (Trunk) n=88,86,44,422.25 ± 0.9132.33 ± 0.8042.89 ± 0.6892.90 ± 0.759
Week 4: Induration (Trunk) n=87,88,43,421.71 ± 1.1091.95 ± 0.9702.67 ± 0.9192.71 ± 0.742
Week 8: Induration (Trunk) n=85,88,40,391.13 ± 1.1421.51 ± 1.0612.25 ± 1.0802.54 ± 0.969
Week 12: Induration (Trunk) n=84,88,40,390.73 ± 1.0341.35 ± 1.1152.00 ± 1.1092.33 ± 0.898
Week 16: Induration (Trunk) n=84,84,38,390.56 ± 0.9611.15 ± 1.1561.79 ± 1.2982.18 ± 0.942
Week 20: Induration (Trunk) n=84,84,38,390.50 ± 0.9761.01 ± 1.0700.97 ± 0.9721.13 ± 0.833
Week 32: Induration (Trunk) n=83,83,38,370.49 ± 0.8460.96 ± 1.0870.50 ± 0.9800.70 ± 0.939
Week 40: Induration (Trunk) n=81,81,37,360.49 ± 0.9100.89 ± 1.0370.38 ± 0.8610.81 ± 1.091
Week 52: Induration (Trunk) n=80,78,36,360.55 ± 0.8990.83 ± 1.0120.50 ± 0.9410.97 ± 1.028
Baseline: Induration (Lower Limbs) n=90,88,44,443.03 ± 0.6782.88 ± 0.7083.02 ± 0.8213.16 ± 0.680
Week 2: Induration (Lower Limbs) n=88,86,44,422.39 ± 0.9152.43 ± 0.8882.93 ± 0.8463.00 ± 0.826
Week 4: Induration (Lower Limbs) n=87,88,43,421.83 ± 1.1022.09 ± 0.9782.81 ± 0.9322.93 ± 0.808
Week 8: Induration (Lower Limbs) n=85,88,40,391.22 ± 1.1381.61 ± 1.0442.43 ± 1.0352.67 ± 0.927
Week 12: Induration (Lower Limbs) n=84,88,40,390.69 ± 0.8781.36 ± 1.0632.15 ± 0.9752.49 ± 0.970
Week 16: Induration (Lower Limbs) n=84,84,38,390.54 ± 0.7981.24 ± 1.1151.95 ± 1.1382.46 ± 0.969
Week 20: Induration (Lower Limbs) n=84,84,38,390.44 ± 0.8271.07 ± 1.0271.05 ± 1.0121.41 ± 0.785
Week 32: Induration (Lower Limbs) n=83,83,38,370.40 ± 0.8261.01 ± 1.0880.58 ± 0.9760.97 ± 1.013
Week 40: Induration (Lower Limbs) n=81,81,37,360.46 ± 0.7910.95 ± 1.0110.68 ± 1.0290.78 ± 0.898
Week 52: Induration (Lower Limbs) n=80,78,36,360.61 ± 0.9071.03 ± 1.0690.67 ± 1.0691.03 ± 1.134
Baseline: Scaling (Head/Neck) n=90,88,44,442.40 ± 0.9462.01 ± 1.0112.25 ± 1.1842.34 ± 0.987
Week 2: Scaling (Head/Neck) n=88,86,44,421.67 ± 1.0031.71 ± 1.0042.11 ± 1.1852.40 ± 0.939
Week 4: Scaling (Head/Neck) n=87,88,43,421.24 ± 1.1311.41 ± 1.0681.84 ± 1.2142.24 ± 0.906
Week 8: Scaling (Head/Neck) n=85,88,40,390.80 ± 0.9861.02 ± 1.0391.48 ± 1.1092.03 ± 1.013
Week 12: Scaling (Head/Neck) n=84,88,40,390.64 ± 0.8870.85 ± 1.0121.38 ± 1.0301.82 ± 0.914
Week 16: Scaling (Head/Neck) n=84,84,38,390.57 ± 0.8110.76 ± 1.0251.21 ± 1.0181.72 ± 0.999
Week 20: Scaling (Head/Neck) n=84,84,38,390.43 ± 0.6640.67 ± 0.8410.58 ± 0.7580.85 ± 0.812
Week 32: Scaling (Head/Neck) n=83,83,38,370.48 ± 0.7390.61 ± 0.8090.29 ± 0.6540.70 ± 0.878
Week 40: Scaling (Head/Neck) n=81,81,37,360.51 ± 0.8390.67 ± 0.8940.35 ± 0.7160.67 ± 0.956
Week 52: Scaling (Head/Neck) n=80,78,36,360.58 ± 0.8970.63 ± 0.8840.36 ± 0.7230.72 ± 0.914
Baseline: Scaling (Upper Limbs) n=90,88,44,442.72 ± 0.7792.60 ± 0.7962.55 ± 0.8482.82 ± 0.724
Week 2: Scaling (Upper Limbs) n=88,86,44,422.00 ± 0.9222.19 ± 0.9522.43 ± 0.9002.62 ± 0.764
Week 4: Scaling (Upper Limbs) n=87,88,43,421.41 ± 1.1061.77 ± 1.0472.28 ± 1.0312.52 ± 0.804
Week 8: Scaling (Upper Limbs) n=85,88,40,390.89 ± 0.9391.35 ± 1.0181.93 ± 1.1182.28 ± 0.887
Week 12: Scaling (Upper Limbs) n=84,88,40,390.56 ± 0.8411.14 ± 1.1061.60 ± 1.0332.23 ± 0.810
Week 16: Scaling (Upper Limbs) n=84,84,38,390.40 ± 0.7930.99 ± 1.0701.50 ± 1.0331.97 ± 0.903
Week 20: Scaling (Upper Limbs) n=84,84,38,390.39 ± 0.8070.86 ± 0.9070.82 ± 0.8341.21 ± 0.833
Week 32: Scaling (Upper Limbs) n=83,83,38,370.36 ± 0.7080.93 ± 1.0100.42 ± 0.6420.81 ± 0.967
Week 40: Scaling (Upper Limbs) n=81,81,37,360.40 ± 0.8010.96 ± 1.0060.41 ± 0.6860.83 ± 0.910
Week 52: Scaling (Upper Limbs) n=80,78,36,360.48 ± 0.7630.95 ± 0.9790.61 ± 0.8710.92 ± 1.052
Baseline: Scaling (Trunk) n=90,88,44,442.72 ± 0.7652.73 ± 0.7842.77 ± 0.6772.93 ± 0.789
Week 2: Scaling (Trunk) n=88,86,44,422.03 ± 0.9282.27 ± 0.9382.66 ± 0.7452.76 ± 0.759
Week 4: Scaling (Trunk) n=87,88,43,421.52 ± 1.1091.92 ± 0.9972.49 ± 0.8832.57 ± 0.770
Week 8: Scaling (Trunk) n=85,88,40,390.95 ± 1.0571.48 ± 1.0392.10 ± 1.0082.38 ± 0.815
Week 12: Scaling (Trunk) n=84,88,40,390.69 ± 1.0061.27 ± 1.1321.73 ± 1.0372.28 ± 0.857
Week 16: Scaling (Trunk) n=84,84,38,390.52 ± 0.9381.02 ± 1.0971.58 ± 1.1062.10 ± 0.882
Week 20: Scaling (Trunk) n=84,84,38,370.49 ± 0.8710.96 ± 0.9870.82 ± 0.9551.13 ± 0.894
Week 32: Scaling (Trunk) n=83,83,38,370.46 ± 0.7540.92 ± 0.9530.39 ± 0.8230.68 ± 0.852
Week 40: Scaling (Trunk) n=81,81,37,360.49 ± 0.8820.91 ± 0.9380.38 ± 0.8610.78 ± 0.989
Week 52: Scaling (Trunk) n=80,78,36,360.55 ± 0.8550.82 ± 0.8180.53 ± 0.9710.89 ± 0.887
Baseline: Scaling (Lower Limbs) n=90,88,44,442.94 ± 0.7092.92 ± 0.7762.84 ± 0.8343.20 ± 0.765
Week 2: Scaling (Lower Limbs) n=88,86,44,422.24 ± 1.0172.40 ± 0.9112.66 ± 0.8882.98 ± 0.841
Week 4: Scaling (Lower Limbs) n=87,88,43,421.72 ± 1.1172.08 ± 0.9972.49 ± 0.9602.76 ± 0.906
Week 8: Scaling (Lower Limbs) n=85,88,40,391.15 ± 1.1291.52 ± 1.0932.20 ± 1.0182.54 ± 0.884
Week 12: Scaling (Lower Limbs) n=84,88,40,390.67 ± 0.8961.32 ± 1.1202.03 ± 0.9202.51 ± 0.885
Week 16: Scaling (Lower Limbs) n=84,84,38,390.46 ± 0.7831.20 ± 1.1061.82 ± 1.0622.38 ± 0.815
Week 20: Scaling (Lower Limbs) n=84,84,38,390.45 ± 0.8701.14 ± 1.0200.95 ± 0.8681.41 ± 0.751
Week 32: Scaling (Lower Limbs) n=83,83,38,370.37 ± 0.7601.08 ± 1.1180.47 ± 0.7971.03 ± 1.013
Week 40: Scaling (Lower Limbs) n=81,81,37,360.53 ± 0.9761.06 ± 1.0410.51 ± 0.7310.83 ± 1.056
Week 52: Scaling (Lower Limbs) n=80,78,36,360.61 ± 0.9211.08 ± 1.0420.67 ± 1.0691.06 ± 1.120
SecondaryChange From Baseline in PASI Component Scores Over Time Through Week 52

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of body surface area (BSA)" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Mean · units on a scale
Change From Baseline in PASI Component Scores Over Time Through Week 52
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 2: Erythema (Head/Neck) n=88,86,44,42)-0.56 ± 0.676-0.41 ± 0.757-0.14 ± 0.5940.10 ± 0.532
Week 4: Erythema (Head/Neck) n=87,88,43,42)-0.94 ± 0.854-0.74 ± 0.890-0.26 ± 0.727-0.17 ± 0.621
Week 8: Erythema (Head/Neck) n=85,88,40,39-1.36 ± 0.962-1.05 ± 1.038-0.20 ± 1.114-0.38 ± 0.935
Week 12: Erythema (Head/Neck) n=84,88,40,39-1.61 ± 0.957-1.24 ± 1.135-0.38 ± 1.295-0.46 ± 0.942
Week 16: Erythema (Head/Neck) n=84,84,38,39-1.70 ± 1.015-1.43 ± 1.175-0.66 ± 1.361-0.62 ± 0.907
Week 20: Erythema (Head/Neck) n=84,84,38,39-1.79 ± 0.945-1.43 ± 1.185-1.37 ± 1.172-1.36 ± 1.158
Week 32: Erythema (Head/Neck) n=83,83,38,37-1.71 ± 1.030-1.51 ± 1.203-1.68 ± 1.254-1.59 ± 1.257
Week 40: Erythema (Head/Neck) n=81,81,37,36-1.78 ± 1.084-1.51 ± 1.195-1.68 ± 1.132-1.81 ± 1.191
Week 52: Erythema (Head/Neck) n=80,78,36,36-1.73 ± 1.079-1.53 ± 1.181-1.61 ± 1.225-1.67 ± 1.265
Week 2: Erythema (Upper Limbs) n=88,86,44,42-0.64 ± 0.698-0.51 ± 0.6090.02 ± 0.4030.14 ± 0.417
Week 4: Erythema (Upper Limbs) n=87,88,43,42-1.09 ± 0.858-0.91 ± 0.839-0.12 ± 0.697-0.05 ± 0.582
Week 8: Erythema (Upper Limbs) n=85,88,40,39-1.65 ± 0.984-1.32 ± 0.977-0.28 ± 0.784-0.26 ± 0.677
Week 12: Erythema (Upper Limbs) n=84,88,40,39-2.08 ± 0.908-1.61 ± 1.159-0.50 ± 0.877-0.41 ± 0.818
Week 16: Erythema (Upper Limbs) n=84,84,38,39-2.17 ± 1.004-1.81 ± 1.092-0.92 ± 0.941-0.44 ± 0.852
Week 20: Erythema (Upper Limbs) n=84,84,38,39-2.27 ± 1.057-1.87 ± 1.117-1.66 ± 0.966-1.38 ± 1.042
Week 32: Erythema (Upper Limbs) n=83,83,38,37-2.29 ± 0.957-1.83 ± 1.257-2.08 ± 1.148-1.89 ± 0.994
Week 40: Erythema (Upper Limbs) n=81,81,37,36-2.26 ± 1.081-1.89 ± 1.151-2.05 ± 1.153-1.94 ± 1.094
Week 52: Erythema (Upper Limbs) n=80,78,36,36-2.14 ± 1.111-1.85 ± 1.185-1.94 ± 1.286-1.83 ± 1.183
Week 2: Erythema (Trunk) n=88,86,44,42-0.57 ± 0.724-0.41 ± 0.639-0.02 ± 0.4570.10 ± 0.370
Week 4: Erythema (Trunk) n=87,88,43,42-1.05 ± 0.888-0.76 ± 0.844-0.14 ± 0.774-0.12 ± 0.550
Week 8: Erythema (Trunk) n=85,88,40,39-1.66 ± 1.041-1.16 ± 0.969-0.35 ± 0.949-0.28 ± 0.560
Week 12: Erythema (Trunk) n=84,88,40,39-2.04 ± 1.092-1.36 ± 1.176-0.65 ± 1.167-0.38 ± 0.711
Week 16: Erythema (Trunk) n=84,84,38,39-2.21 ± 1.054-1.61 ± 1.203-0.97 ± 1.262-0.28 ± 0.793
Week 20: Erythema (Trunk) n=84,84,38,39-2.23 ± 1.134-1.70 ± 1.200-1.76 ± 1.025-1.62 ± 1.091
Week 32: Erythema (Trunk) n=83,83,38,37-2.25 ± 1.034-1.80 ± 1.276-2.32 ± 1.016-2.22 ± 1.004
Week 40: Erythema (Trunk) n=81,81,37,36-2.36 ± 1.028-1.86 ± 1.212-2.43 ± 0.929-2.22 ± 1.072
Week 52: Erythema (Trunk) n=80,78,36,36-2.24 ± 1.082-1.82 ± 1.256-2.22 ± 1.174-1.97 ± 1.158
Week 2: Erythema (Lower Limbs) n=88,86,44,42-0.50 ± 0.587-0.38 ± 0.7220.00 ± 0.3740.05 ± 0.379
Week 4: Erythema (Lower Limbs) n=87,88,43,42-1.07 ± 0.860-0.75 ± 0.820-0.12 ± 0.625-0.12 ± 0.593
Week 8: Erythema (Lower Limbs) n=85,88,40,39-1.71 ± 1.010-1.19 ± 1.123-0.33 ± 0.764-0.26 ± 0.637
Week 12: Erythema (Lower Limbs) n=84,88,40,39-2.24 ± 0.965-1.44 ± 1.183-0.58 ± 0.958-0.36 ± 0.778
Week 16: Erythema (Lower Limbs) n=84,84,38,39-2.36 ± 1.014-1.55 ± 1.255-0.89 ± 1.085-0.41 ± 0.818
Week 20: Erythema (Lower Limbs) n=84,84,38,39-2.49 ± 1.000-1.73 ± 1.274-1.87 ± 0.991-1.41 ± 0.993
Week 32: Erythema (Lower Limbs) n=83,83,38,37-2.54 ± 1.028-1.86 ± 1.372-2.37 ± 1.025-2.05 ± 1.129
Week 40: Erythema (Lower Limbs) n=81,81,37,36-2.52 ± 1.062-1.86 ± 1.243-2.32 ± 1.082-2.33 ± 1.121
Week 52: Erythema (Lower Limbs) n=80,78,36,36-2.33 ± 1.077-1.74 ± 1.400-2.25 ± 1.251-2.19 ± 1.215
Week 2: Induration (Head/Neck) n=88,86,44,42-0.59 ± 0.705-0.27 ± 0.602-0.07 ± 0.398-0.02 ± 0.468
Week 4: Induration (Head/Neck) n=87,88,43,42-1.07 ± 0.974-0.59 ± 0.892-0.30 ± 0.708-0.12 ± 0.670
Week 8: Induration (Head/Neck) n=85,88,40,39-1.38 ± 1.080-0.86 ± 0.937-0.50 ± 1.086-0.33 ± 0.927
Week 12: Induration (Head/Neck) n=84,88,40,39-1.58 ± 1.032-1.08 ± 1.031-0.65 ± 1.075-0.54 ± 0.913
Week 16: Induration (Head/Neck) n=84,84,38,39-1.70 ± 1.106-1.24 ± 1.060-0.76 ± 1.240-0.69 ± 0.863
Week 20: Induration (Head/Neck) n=84,84,38,39-1.81 ± 1.058-1.30 ± 1.084-1.47 ± 1.133-1.36 ± 0.903
Week 32: Induration (Head/Neck) n=83,83,38,37-1.71 ± 1.121-1.41 ± 1.094-1.74 ± 1.155-1.65 ± 1.160
Week 40: Induration (Head/Neck) n=81,81,37,36-1.75 ± 1.124-1.37 ± 1.066-1.68 ± 1.056-1.78 ± 1.198
Week 52: Induration (Head/Neck) n=80,78,36,36-1.68 ± 1.178-1.36 ± 1.139-1.58 ± 1.228-1.69 ± 1.215
Week 2: Induration (Upper Limbs) n=88,86,44,42-0.68 ± 0.766-0.42 ± 0.727-0.05 ± 0.526-0.07 ± 0.407
Week 4: Induration (Upper Limbs) n=87,88,43,42-1.17 ± 1.048-0.77 ± 0.867-0.21 ± 0.833-0.19 ± 0.707
Week 8: Induration (Upper Limbs) n=85,88,40,39-1.69 ± 1.024-1.19 ± 1.092-0.55 ± 1.011-0.41 ± 0.751
Week 12: Induration (Upper Limbs) n=84,88,40,39-2.17 ± 0.862-1.47 ± 1.231-0.80 ± 1.091-0.54 ± 0.822
Week 16: Induration (Upper Limbs) n=84,84,38,39-2.32 ± 0.867-1.52 ± 1.217-1.05 ± 1.293-0.69 ± 0.977
Week 20: Induration (Upper Limbs) n=84,84,38,39-2.35 ± 1.012-1.67 ± 1.186-1.71 ± 1.250-1.59 ± 1.093
Week 32: Induration (Upper Limbs) n=83,83,38,37-2.29 ± 1.018-1.61 ± 1.296-2.03 ± 1.150-1.97 ± 1.093
Week 40: Induration (Upper Limbs) n=81,81,37,36-2.25 ± 1.067-1.65 ± 1.266-2.11 ± 1.100-1.97 ± 1.108
Week 52: Induration (Upper Limbs) n=80,78,36,36-2.20 ± 1.107-1.69 ± 1.282-2.03 ± 1.183-1.92 ± 1.204
Week 2: Induration (Trunk) n=88,86,44,42-0.65 ± 0.728-0.43 ± 0.660-0.02 ± 0.457-0.05 ± 0.439
Week 4: Induration (Trunk) n=87,88,43,42-1.20 ± 1.044-0.78 ± 0.850-0.23 ± 0.812-0.24 ± 0.576
Week 8: Induration (Trunk) n=85,88,40,39-1.78 ± 1.084-1.23 ± 1.003-0.68 ± 1.071-0.38 ± 0.673
Week 12: Induration (Trunk) n=84,88,40,39-2.19 ± 1.035-1.39 ± 1.129-0.90 ± 1.194-0.59 ± 0.637
Week 16: Induration (Trunk) n=84,84,38,39-2.36 ± 0.965-1.57 ± 1.154-1.13 ± 1.398-0.74 ± 0.785
Week 20: Induration (Trunk) n=84,84,38,39-2.42 ± 0.984-1.71 ± 1.071-1.95 ± 1.138-1.79 ± 1.031
Week 32: Induration (Trunk) n=83,83,38,37-2.41 ± 0.938-1.76 ± 1.122-2.42 ± 1.222-2.22 ± 1.158
Week 40: Induration (Trunk) n=81,81,37,36-2.41 ± 1.058-1.84 ± 1.145-2.57 ± 1.068-2.08 ± 1.360
Week 52: Induration (Trunk) n=80,78,36,36-2.36 ± 1.070-1.90 ± 1.180-2.47 ± 1.207-1.92 ± 1.339
Week 2: Induration (Lower Limbs) n=88,86,44,42-0.65 ± 0.803-0.43 ± 0.660-0.09 ± 0.421-0.14 ± 0.417
Week 4: Induration (Lower Limbs) n=87,88,43,42-1.22 ± 0.993-0.78 ± 0.809-0.21 ± 0.773-0.21 ± 0.415
Week 8: Induration (Lower Limbs) n=85,88,40,39-1.82 ± 1.002-1.26 ± 0.977-0.60 ± 0.955-0.49 ± 0.683
Week 12: Induration (Lower Limbs) n=84,88,40,39-2.36 ± 0.845-1.51 ± 1.093-0.85 ± 0.975-0.67 ± 0.772
Week 16: Induration (Lower Limbs) n=84,84,38,39-2.51 ± 0.814-1.63 ± 1.159-1.08 ± 1.148-0.69 ± 0.766
Week 20: Induration (Lower Limbs) n=84,84,38,39-2.61 ± 0.865-1.80 ± 1.039-1.97 ± 1.026-1.74 ± 0.818
Week 32: Induration (Lower Limbs) n=83,83,38,37-2.64 ± 0.957-1.86 ± 1.106-2.45 ± 1.083-2.14 ± 1.058
Week 40: Induration (Lower Limbs) n=81,81,37,36-2.57 ± 0.974-1.93 ± 1.022-2.35 ± 1.033-2.31 ± 1.064
Week 52: Induration (Lower Limbs) n=80,78,36,36-2.43 ± 1.041-1.85 ± 1.140-2.39 ± 1.178-2.06 ± 1.194
Week 2: Scaling (Head/Neck) n=88,86,44,42-0.72 ± 0.802-0.28 ± 0.587-0.14 ± 0.5940.05 ± 0.379
Week 4: Scaling (Head/Neck) n=87,88,43,42-1.16 ± 1.077-0.60 ± 0.766-0.40 ± 0.955-0.12 ± 0.633
Week 8: Scaling (Head/Neck) n=85,88,40,39-1.60 ± 1.157-0.99 ± 1.000-0.75 ± 1.296-0.38 ± 0.963
Week 12: Scaling (Head/Neck) n=84,88,40,39-1.76 ± 1.137-1.16 ± 1.103-0.83 ± 1.338-0.59 ± 0.993
Week 16: Scaling (Head/Neck) n=84,84,38,39-1.83 ± 1.160-1.31 ± 1.151-0.97 ± 1.404-0.69 ± 0.977
Week 20: Scaling (Head/Neck) n=84,84,38,39-1.98 ± 1.075-1.40 ± 1.110-1.61 ± 1.366-1.56 ± 1.021
Week 32: Scaling (Head/Neck) n=83,83,38,37-1.92 ± 1.073-1.47 ± 1.162-1.89 ± 1.290-1.70 ± 1.266
Week 40: Scaling (Head/Neck) n=81,81,37,36-1.88 ± 1.198-1.41 ± 1.138-1.78 ± 1.250-1.78 ± 1.267
Week 52: Scaling (Head/Neck) n=80,78,36,36-1.81 ± 1.192-1.45 ± 1.202-1.78 ± 1.456-1.72 ± 1.233
Week 2: Scaling (Upper Limbs) n=88,86,44,42-0.72 ± 0.843-0.41 ± 0.602-0.11 ± 0.579-0.19 ± 0.634
Week 4: Scaling (Upper Limbs) n=87,88,43,42-1.31 ± 1.154-0.83 ± 0.847-0.26 ± 0.848-0.29 ± 0.742
Week 8: Scaling (Upper Limbs) n=85,88,40,39-1.84 ± 1.078-1.25 ± 0.950-0.63 ± 1.030-0.56 ± 0.940
Week 12: Scaling (Upper Limbs) n=84,88,40,39-2.18 ± 0.894-1.47 ± 1.114-0.93 ± 1.023-0.62 ± 1.016
Week 16: Scaling (Upper Limbs) n=84,84,38,39-2.33 ± 0.998-1.62 ± 1.040-1.00 ± 1.115-0.87 ± 1.105
Week 20: Scaling (Upper Limbs) n=84,84,38,39-2.35 ± 1.047-1.75 ± 1.005-1.68 ± 1.093-1.64 ± 1.112
Week 32: Scaling (Upper Limbs) n=83,83,38,37-2.37 ± 1.009-1.67 ± 1.025-2.08 ± 0.997-2.03 ± 1.258
Week 40: Scaling (Upper Limbs) n=81,81,37,36-2.32 ± 1.127-1.65 ± 1.153-2.08 ± 1.064-2.00 ± 1.195
Week 52: Scaling (Upper Limbs) n=80,78,36,36-2.25 ± 1.175-1.68 ± 1.201-1.89 ± 1.282-1.92 ± 1.381
Week 2: Scaling (Trunk) n=88,86,44,42-0.68 ± 0.810-0.49 ± 0.682-0.11 ± 0.655-0.17 ± 0.490
Week 4: Scaling (Trunk) n=87,88,43,42-1.22 ± 1.104-0.81 ± 0.842-0.28 ± 0.934-0.36 ± 0.692
Week 8: Scaling (Trunk) n=85,88,40,39-1.79 ± 1.124-1.25 ± 0.997-0.70 ± 1.018-0.54 ± 0.790
Week 12: Scaling (Trunk) n=84,88,40,39-2.06 ± 1.045-1.45 ± 1.174-1.05 ± 1.154-0.64 ± 0.932
Week 16: Scaling (Trunk) n=84,84,38,39-2.23 ± 1.090-1.71 ± 1.136-1.21 ± 1.255-0.82 ± 0.970
Week 20: Scaling (Trunk) n=84,84,38,39-2.26 ± 1.088-1.77 ± 1.090-1.97 ± 1.219-1.79 ± 1.174
Week 32: Scaling (Trunk) n=83,83,38,37-2.28 ± 0.992-1.82 ± 1.049-2.39 ± 1.054-2.22 ± 1.250
Week 40: Scaling (Trunk) n=81,81,37,36-2.22 ± 1.173-1.83 ± 1.160-2.43 ± 1.042-2.11 ± 1.410
Week 52: Scaling (Trunk) n=80,78,36,36-2.18 ± 1.188-1.94 ± 1.049-2.31 ± 1.215-2.00 ± 1.352
Week 2: Scaling (Lower Limbs) n=88,86,44,42-0.70 ± 0.846-0.51 ± 0.778-0.18 ± 0.657-0.21 ± 0.565
Week 4: Scaling (Lower Limbs) n=87,88,43,42-1.22 ± 1.016-0.84 ± 0.933-0.35 ± 0.997-0.43 ± 0.668
Week 8: Scaling (Lower Limbs) n=85,88,40,39-1.80 ± 1.044-1.40 ± 1.078-0.63 ± 1.125-0.69 ± 0.863
Week 12: Scaling (Lower Limbs) n=84,88,40,39-2.30 ± 0.915-1.60 ± 1.160-0.75 ± 1.080-0.72 ± 0.916
Week 16: Scaling (Lower Limbs) n=84,84,38,39-2.50 ± 0.912-1.74 ± 1.173-0.95 ± 1.293-0.85 ± 1.014
Week 20: Scaling (Lower Limbs) n=84,84,38,39-2.51 ± 0.963-1.80 ± 1.138-1.82 ± 1.136-1.82 ± 1.023
Week 32: Scaling (Lower Limbs) n=83,83,38,37-2.58 ± 0.964-1.86 ± 1.128-2.29 ± 1.160-2.16 ± 1.236
Week 40: Scaling (Lower Limbs) n=81,81,37,36-2.40 ± 1.190-1.89 ± 1.118-2.22 ± 1.004-2.33 ± 1.331
Week 52: Scaling (Lower Limbs) n=80,78,36,36-2.33 ± 1.111-1.88 ± 1.151-2.08 ± 1.360-2.11 ± 1.326
SecondaryPercent Change From Baseline in PASI Scores Over Time Through Week 52

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in PASI Scores Over Time Through Week 52
percent changeTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 2 (n=88,86,44,42)-24.93 ± 2.399-16.28 ± 2.4091.37 ± 3.392-0.35 ± 3.473
Week 4 (n=87,88,43,42)-46.24 ± 3.135-32.47 ± 3.127-1.98 ± 4.444-7.31 ± 4.527
Week 8 (n=85,88,40,39)-66.96 ± 3.769-51.24 ± 3.739-13.17 ± 5.384-16.18 ± 5.488
Week 12 (n=84,88,40,39)-80.64 ± 3.631-59.73 ± 3.585-25.13 ± 5.205-20.40 ± 5.304
Week 16 (n=84,84,38,39)-84.35 ± 3.912-66.69 ± 3.874-32.79 ± 5.651-21.63 ± 5.721
Week 20 (n=84,84,38,39)-87.89 ± 3.024-71.93 ± 3.002-69.85 ± 4.399-60.85 ± 4.423
Week 32 (n=83,83,38,37)-90.47 ± 2.444-76.06 ± 2.437-86.63 ± 3.584-81.43 ± 3.622
Week 40 (n=81,81,37,36)-90.18 ± 2.264-77.29 ± 2.258-87.73 ± 3.332-83.64 ± 3.368
Week 52 (n=80,78,36,36)-86.05 ± 2.763-75.55 ± 2.764-84.65 ± 4.066-79.27 ± 4.101
SecondaryActual BSA Over Time Through Week 52

Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Mean · percent BSA
Actual BSA Over Time Through Week 52
percent BSATofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Baseline (n=90,88,44,44)36.36 ± 18.03537.41 ± 19.61435.29 ± 18.29436.25 ± 16.018
Week 2 (n=88,86,44,44)33.95 ± 17.53736.56 ± 19.36336.84 ± 18.80836.38 ± 16.592
Week 4 (n=87,88,43,42)27.82 ± 18.59932.75 ± 18.31438.32 ± 19.35536.30 ± 16.916
Week 8 (n=85,88,40,39)17.62 ± 18.41124.38 ± 19.58336.75 ± 19.81734.99 ± 16.182
Week 12 (n=84,88,40,39)10.59 ± 15.48620.45 ± 20.46233.15 ± 20.48334.06 ± 17.142
Week 16 (n=84,84,38,39)7.57 ± 13.39516.52 ± 18.89928.57 ± 21.64534.54 ± 18.293
Week 20 (n=84,84,38,39)5.05 ± 10.04113.69 ± 16.97615.50 ± 16.52224.83 ± 19.044
Week 32 (n=83,83,38,37)3.22 ± 5.89411.47 ± 16.3046.95 ± 10.2629.03 ± 11.781
Week 40 (n=81,81,37,36)2.56 ± 5.41210.32 ± 13.0775.88 ± 8.3516.35 ± 9.462
Week 52 (n=80,78,36,36)3.83 ± 7.90810.94 ± 15.2555.00 ± 7.6867.87 ± 9.584
SecondaryPercent Change From Baseline in BSA Over Time Through Week 52

Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

Time frame:
Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in BSA Over Time Through Week 52
percent changeTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 2 (n=88,86,44,44)-5.58 ± 2.083-2.53 ± 2.0934.79 ± 2.9472.14 ± 3.016
Week 4 (n=87,88,43,42)-21.90 ± 3.202-10.98 ± 3.19310.29 ± 4.5412.28 ± 4.622
Week 8 (n=85,88,40,39)-46.98 ± 4.909-33.22 ± 4.8708.73 ± 7.017-0.42 ± 7.155
Week 12 (n=84,88,40,39)-65.97 ± 5.536-44.44 ± 5.4710.41 ± 7.9280.48 ± 8.086
Week 16 (n=84,84,38,39)-73.80 ± 5.903-54.41 ± 5.839-8.85 ± 8.5114.13 ± 8.632
Week 20 (n=84,84,38,39)-82.65 ± 4.459-62.35 ± 4.419-49.35 ± 6.495-28.86 ± 6.530
Week 32 (n=83,83,38,37)-87.55 ± 3.531-70.55 ± 3.521-74.83 ± 5.186-73.95 ± 5.235
Week 40 (n=81,81,37,36)-90.00 ± 3.213-73.00 ± 3.207-79.48 ± 4.743-79.91 ± 4.786
Week 52 (n=80,78,36,36)-84.16 ± 3.867-72.28 ± 3.868-81.70 ± 5.681-74.02 ± 5.737
SecondaryPercentage of Participants With PASI50 Response Over Time Through Week 52

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. Percentage of participants with PASI50 response is reported.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With PASI50 Response Over Time Through Week 52
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 221.11 (12.68 to 29.54)5.68 (0.85 to 10.52)0.00 (NA to NA)0.00 (NA to NA)
Week 448.89 (38.56 to 59.22)27.27 (17.97 to 36.58)4.55 (0.00 to 10.70)4.55 (0.00 to 10.70)
Week 874.44 (65.43 to 83.46)55.68 (45.30 to 66.06)13.64 (3.50 to 23.78)4.55 (0.00 to 10.70)
Week 1281.11 (73.02 to 89.20)64.77 (54.79 to 74.75)27.27 (14.11 to 40.43)9.09 (0.60 to 17.59)
Week 1686.67 (79.64 to 93.69)71.59 (62.17 to 81.01)40.91 (26.38 to 55.44)18.18 (6.79 to 29.58)
Week 2085.56 (78.29 to 92.82)72.73 (63.42 to 82.03)68.18 (54.42 to 81.94)63.64 (49.42 to 77.85)
Week 3288.89 (82.40 to 95.38)78.41 (69.81 to 87.01)79.55 (67.63 to 91.46)75.00 (62.21 to 87.79)
Week 4087.78 (81.01 to 94.54)80.68 (72.43 to 88.93)79.55 (67.63 to 91.46)72.73 (59.57 to 85.89)
Week 5283.33 (75.63 to 91.03)73.86 (64.68 to 83.04)77.27 (64.89 to 89.66)75.00 (62.21 to 87.79)
SecondaryPercentage of Participants With PASI90 Response Over Time Through Week 52

The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least 90% reduction in PASI relative to Baseline. Percentage of participants with PASI90 response up to Week 52 is reported.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With PASI90 Response Over Time Through Week 52
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 20.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)
Week 47.78 (2.24 to 13.31)2.27 (0.00 to 5.39)0.00 (NA to NA)0.00 (NA to NA)
Week 827.78 (18.52 to 37.03)13.64 (6.47 to 20.81)0.00 (NA to NA)0.00 (NA to NA)
Week 1251.11 (40.78 to 61.44)29.55 (20.01 to 39.08)0.00 (NA to NA)0.00 (NA to NA)
Week 1660.00 (49.88 to 70.12)35.23 (25.25 to 45.21)6.82 (0.00 to 14.27)0.00 (NA to NA)
Week 2071.11 (61.75 to 80.48)35.23 (25.25 to 45.21)25.00 (12.21 to 37.79)9.09 (0.60 to 17.59)
Week 3265.56 (55.74 to 75.37)42.05 (31.73 to 52.36)56.82 (42.18 to 71.45)40.91 (26.38 to 55.44)
Week 4066.67 (56.93 to 76.41)35.23 (25.25 to 45.21)56.82 (42.18 to 71.45)45.45 (30.74 to 60.17)
Week 5256.67 (46.43 to 66.90)38.64 (28.46 to 48.81)56.82 (42.18 to 71.45)36.36 (22.15 to 50.58)
SecondaryPercentage of Participants With PASI125 Over Time Through Week 52

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percentage of participants with PASI score of at least 125% of baseline PASI score are reported.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With PASI125 Over Time Through Week 52
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 2 (n=88,86,44,42)2.27 (0.00 to 5.39)1.16 (0.00 to 3.43)4.55 (0.00 to 10.70)4.76 (0.00 to 11.20)
Week 4 (n=87,88,43,42)2.30 (0.00 to 5.45)1.14 (0.00 to 3.35)13.95 (3.60 to 24.31)2.38 (0.00 to 6.99)
Week 8 (n=85,88,40,39)2.35 (0.00 to 5.58)1.14 (0.00 to 3.35)17.50 (5.72 to 29.28)2.56 (0.00 to 7.52)
Week 12 (n=84,88,40,39)1.19 (0.00 to 3.51)1.14 (0.00 to 3.35)7.50 (0.00 to 15.66)5.13 (0.00 to 12.05)
Week 16 (n=84,84,38,39)1.19 (0.00 to 3.51)2.38 (0.00 to 5.64)10.53 (0.77 to 20.28)7.69 (0.00 to 16.06)
Week 20 (n=84,84,38,39)1.19 (0.00 to 3.51)0.00 (NA to NA)0.00 (NA to NA)2.56 (0.00 to 7.52)
Week 32 (n=83,83,38,37)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)
Week 40 (n=81,81,37,36)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)
Week 52 (n=80,78,36,36)1.25 (0.00 to 3.68)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)
SecondaryActual Nail Psoriasis Severity Index (NAPSI) Score Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.

Time frame:
Baseline and Weeks 8, 16, 20, 32, 40, and 52
Reported as:
Mean · units on a scale
Actual Nail Psoriasis Severity Index (NAPSI) Score Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Baseline (n=40,38,18,18)25.8 ± 20.5826.2 ± 16.9728.7 ± 21.9025.2 ± 16.37
Week 8 (n=39,38,15,15)23.0 ± 19.4523.6 ± 17.2928.6 ± 23.6630.7 ± 18.48
Week 16 (n=38,38,14,15)17.2 ± 19.1419.8 ± 18.3030.3 ± 23.8628.9 ± 20.54
Week 20 (n=37,38,14,15)13.9 ± 18.7017.2 ± 16.9428.6 ± 24.0230.1 ± 19.08
Week 32 (n=37,37,14,14)12.6 ± 19.5915.5 ± 16.6916.2 ± 18.4817.1 ± 12.69
Week 40 (n=36,36,13,13)9.6 ± 18.6514.9 ± 16.0115.7 ± 15.8214.5 ± 13.93
Week 52 (n=31,34,12,13)10.0 ± 20.2213.2 ± 17.9613.8 ± 18.5410.5 ± 12.67
SecondaryChange From Baseline in NAPSI Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail was divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.

Time frame:
Baseline and weeks 8, 16, 20, 32, 40, and 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in NAPSI Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 8 (n=39,38,15,15)-3.60 ± 1.416-2.76 ± 1.4342.17 ± 2.2822.64 ± 2.283
Week 16 (n=38,38,14,15)-9.38 ± 1.927-6.63 ± 1.9362.04 ± 3.1510.84 ± 3.082
Week 20 (n=37,38,14,15)-12.68 ± 1.886-9.18 ± 1.8840.48 ± 3.0792.04 ± 2.999
Week 32 (n=37,37,14,14)-14.02 ± 2.350-11.31 ± 2.350-11.81 ± 3.834-12.61 ± 3.788
Week 40 (n=36,36,13,13)-16.31 ± 2.365-11.94 ± 2.359-13.42 ± 3.876-14.19 ± 3.842
Week 52 (n=31,34,12,13)-17.13 ± 2.689-13.55 ± 2.651-15.08 ± 4.387-17.89 ± 4.315
SecondaryNumber of Affected Nails in Participants With Nail Psoriasis at Baseline Over Time Through Week 52

Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported. The total number of affected FINGER nails was reported.

Time frame:
Baseline and Weeks 8, 16, 20, 32, 40, and 52
Reported as:
Mean · nails
Number of Affected Nails in Participants With Nail Psoriasis at Baseline Over Time Through Week 52
nailsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Baseline (n=40,38,18,18)7.6 ± 3.067.3 ± 3.218.1 ± 2.977.4 ± 3.45
Week 8 (n=39,38,15,15)7.2 ± 3.077.2 ± 3.617.3 ± 3.587.9 ± 3.20
Week 16 (n=38,38,14,15)6.1 ± 3.536.6 ± 3.577.9 ± 3.827.6 ± 3.56
Week 20 (n=37,38,14,15)5.1 ± 3.846.0 ± 3.847.4 ± 3.937.9 ± 3.08
Week 32 (n=37,37,14,14)3.8 ± 3.925.5 ± 3.856.1 ± 3.957.6 ± 3.72
Week 40 (n=36,36,13,13)3.0 ± 3.605.4 ± 4.086.3 ± 4.395.8 ± 4.28
Week 52 (n=31,34,12,13)3.0 ± 3.674.4 ± 4.234.6 ± 4.124.4 ± 3.75
SecondaryPercent Change From Baseline in NAPSI Over Time Through Week 52

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.

Time frame:
Baseline and weeks 8, 16, 20, 32, 40, and 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in NAPSI Over Time Through Week 52
percent changeTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 8 (n=39,38,15,15)-9.59 ± 8.473-8.81 ± 8.5855.28 ± 13.66125.40 ± 13.662
Week 16 (n=38,38,14,15)-33.31 ± 10.552-14.91 ± 10.600-3.26 ± 17.25718.43 ± 16.869
Week 20 (n=37,38,14,15)-51.97 ± 8.748-25.10 ± 8.715-8.87 ± 14.27613.72 ± 13.869
Week 32 (n=37,37,14,14)-58.44 ± 10.256-25.27 ± 10.247-50.20 ± 16.734-45.83 ± 16.481
Week 40 (n=36,36,13,13)-68.68 ± 9.243-37.40 ± 9.208-47.17 ± 15.143-58.60 ± 14.988
Week 52 (n=31,34,12,13)-71.40 ± 10.891-51.71 ± 10.636-56.08 ± 17.621-45.67 ± 17.192
SecondaryPercentage of Participants With NAPSI75 Response Over Time Through Week 52

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported.

Time frame:
Weeks 8, 16, 20, 32, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With NAPSI75 Response Over Time Through Week 52
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 80.00 (NA to NA)10.53 (0.77 to 20.28)5.56 (0.00 to 16.14)0.00 (NA to NA)
Week 1620.00 (7.60 to 32.40)15.79 (4.20 to 27.38)11.11 (0.00 to 25.63)5.56 (0.00 to 16.14)
Week 2030.00 (15.80 to 44.20)13.16 (2.41 to 23.91)11.11 (0.00 to 25.63)0.00 (NA to NA)
Week 3252.50 (37.02 to 67.98)28.95 (14.53 to 43.37)27.78 (7.09 to 48.47)16.67 (0.00 to 33.88)
Week 4065.00 (50.22 to 79.78)34.21 (19.13 to 49.29)33.33 (11.56 to 55.11)33.33 (11.56 to 55.11)
Week 5252.50 (37.02 to 67.98)47.37 (31.49 to 63.24)38.89 (16.37 to 61.41)38.89 (16.37 to 61.41)
SecondaryPercentage of Participants With NAPSI100 Response Over Time Through Week 52

The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported.

Time frame:
Weeks 8, 16, 20, 32, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With NAPSI100 Response Over Time Through Week 52
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 80.00 (NA to NA)5.26 (0.00 to 12.36)0.00 (NA to NA)0.00 (NA to NA)
Week 165.00 (0.00 to 11.75)5.26 (0.00 to 12.36)11.11 (0.00 to 25.63)5.56 (0.00 to 16.14)
Week 2017.50 (5.72 to 29.28)10.53 (0.77 to 20.28)11.11 (0.00 to 25.63)0.00 (NA to NA)
Week 3227.50 (13.66 to 41.34)13.16 (2.41 to 23.91)11.11 (0.00 to 25.63)5.56 (0.00 to 16.14)
Week 4030.00 (15.80 to 44.20)15.79 (4.20 to 27.38)11.11 (0.00 to 25.63)16.67 (0.00 to 33.88)
Week 5230.00 (15.80 to 44.20)31.58 (16.80 to 46.36)16.67 (0.00 to 33.88)16.67 (0.00 to 33.88)
SecondaryActual Itch Severity Item (ISI) Score Over Time Through Week 52

ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Mean · units on a scale
Actual Itch Severity Item (ISI) Score Over Time Through Week 52
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Baseline (n=88,88,44,44)5.66 ± 2.5865.10 ± 2.6795.22 ± 2.5015.75 ± 2.679
Week 2 (n=87,86,44,42)2.97 ± 2.0433.49 ± 2.6695.45 ± 2.7914.95 ± 2.731
Week 4 (n=88,88,43,42)2.13 ± 2.0612.68 ± 2.3225.23 ± 2.7155.12 ± 2.491
Week 8 (n=85,88,40,39)1.47 ± 1.9002.41 ± 2.2834.75 ± 2.6774.97 ± 2.978
Week 12 (n=84,88,40,39)1.24 ± 1.5652.13 ± 2.3234.00 ± 2.6215.00 ± 2.938
Week 16 (n=84,84,38,39)1.17 ± 1.7822.01 ± 2.3673.89 ± 2.3915.13 ± 2.811
Week 20 (n=83,84,38,38)1.06 ± 1.5642.01 ± 2.3261.95 ± 2.2532.11 ± 2.227
Week 32 (n=838238,370.88 ± 1.2732.07 ± 2.3821.24 ± 1.7471.51 ± 2.388
Week 40 (n=81,81,37,36)0.96 ± 1.1452.30 ± 2.2831.49 ± 2.1811.53 ± 2.158
Week 52 (n=80,78,36,36)1.45 ± 2.0742.55 ± 2.5161.89 ± 2.4822.36 ± 2.380
SecondaryChange From Baseline in ISI Score Over Time Through Week 52

ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in ISI Score Over Time Through Week 52
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 2 (n=86,86,44,42)-2.50 ± 0.219-1.76 ± 0.2180.12 ± 0.306-0.64 ± 0.314
Week 4 (n=87,88,43,42)-3.33 ± 0.226-2.60 ± 0.224-0.03 ± 0.319-0.47 ± 0.325
Week 8 (n=84,88,40,39)-3.93 ± 0.232-2.88 ± 0.228-0.50 ± 0.331-0.46 ± 0.337
Week 12 (n=83,88,40,39)-4.10 ± 0.237-3.16 ± 0.233-1.15 ± 0.338-0.44 ± 0.344
Week 16 (n=83,84,38,39)-4.21 ± 0.232-3.28 ± 0.229-1.30 ± 0.335-0.33 ± 0.337
Week 20 (n=82,84,38,38)-4.32 ± 0.219-3.28 ± 0.216-3.22 ± 0.318-3.36 ± 0.320
Week 32 (n=82,82,38,37)-4.51 ± 0.220-3.17 ± 0.219-4.01 ± 0.322-4.04 ± 0.325
Week 40 (n=80,81,37,36)-4.39 ± 0.224-2.98 ± 0.222-3.81 ± 0.328-3.89 ± 0.331
Week 52 (n=79,78,36,36)-3.91 ± 0.272-2.71 ± 0.272-3.47 ± 0.401-3.11 ± 0.403
SecondaryActual Dermatology Life Quality Index (DLQI) Score Over Time Through Week 52

The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Mean · units on a scale
Actual Dermatology Life Quality Index (DLQI) Score Over Time Through Week 52
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Baseline (n=90,88,44,44)14.1 ± 7.1713.5 ± 7.2912.5 ± 6.8212.1 ± 6.92
Week 2 (n=88,86,44,42)9.5 ± 5.3110.0 ± 6.2012.6 ± 7.3410.4 ± 5.97
Week 4 (n=86,88,42,41)7.6 ± 5.008.2 ± 5.4612.4 ± 7.9910.3 ± 5.39
Week 8 (n=85,88,40,39)5.9 ± 5.497.5 ± 5.8911.2 ± 7.259.9 ± 6.66
Week 12 (n=84,88,39,39)4.6 ± 4.476.7 ± 6.1611.1 ± 7.1110.2 ± 6.86
Week 16 (n=84,84,38,39)4.3 ± 4.706.2 ± 5.6210.7 ± 7.2010.5 ± 6.77
Week 20 (n=82,84,38,39)3.8 ± 4.465.4 ± 5.506.2 ± 4.806.4 ± 5.17
Week 32 (n=83,82,38,37)3.2 ± 4.395.1 ± 5.314.7 ± 5.425.0 ± 6.03
Week 40 (n=81,81,37,36)3.7 ± 4.375.9 ± 5.444.6 ± 5.074.1 ± 4.03
Week 52 (n=80,78,35,36)4.6 ± 5.836.5 ± 6.254.7 ± 5.856.0 ± 5.68
SecondaryChange From Baseline in DLQI Score Over Time Through Week 52

The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in DLQI Score Over Time Through Week 52
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 2 (n=88,86,44,42)-3.98 ± 0.455-3.26 ± 0.458-0.20 ± 0.644-2.27 ± 0.659
Week 4 (n=86,88,44,42)-5.96 ± 0.492-5.11 ± 0.4880.17 ± 0.700-2.26 ± 0.712
Week 8 (n=85,88,40,39)-7.52 ± 0.594-5.83 ± 0.587-1.00 ± 0.852-2.70 ± 0.868
Week 12 (n=84,88,39,39)-8.59 ± 0.618-6.64 ± 0.609-0.76 ± 0.891-2.44 ± 0.904
Week 16 (n=84,84,38,39)-9.03 ± 0.618-7.00 ± 0.611-1.15 ± 0.899-2.22 ± 0.905
Week 20 (n=82,84,38,39)-9.36 ± 0.562-7.78 ± 0.555-5.84 ± 0.819-6.30 ± 0.821
Week 32 (n=83,82,38,37)-10.05 ± 0.565-8.07 ± 0.562-7.44 ± 0.828-7.94 ± 0.837
Week 40 (n=81,81,37,36)-9.56 ± 0.563-7.32 ± 0.559-7.61 ± 0.826-8.28 ± 0.836
Week 52 (n=80,78,35,36)-8.63 ± 0.679-6.63 ± 0.681-7.42 ± 1.012-6.37 ± 1.010
SecondaryPercentage of Participants With Patient Global Assessment (PtGA) Response of "Clear" or "Almost Clear" Over Time Through Week 52

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear \[no psoriasis\]; 1=almost clear; 2=mild; 3=moderate; 4=severe). the percentage of participants with scores of 0 (clear) and 1 (almost clear) are reported.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Patient Global Assessment (PtGA) Response of "Clear" or "Almost Clear" Over Time Through Week 52
percentage of participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 20.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)
Week 47.78 (2.24 to 13.31)5.68 (0.85 to 10.52)2.27 (0.00 to 6.68)0.00 (NA to NA)
Week 832.22 (22.57 to 41.88)19.32 (11.07 to 27.57)2.27 (0.00 to 6.68)0.00 (NA to NA)
Week 1245.56 (35.27 to 55.84)27.27 (17.97 to 36.58)2.27 (0.00 to 6.68)0.00 (NA to NA)
Week 1655.56 (45.29 to 65.82)34.09 (24.19 to 43.99)9.09 (0.60 to 17.59)4.55 (0.00 to 10.70)
Week 2052.22 (41.90 to 62.54)31.82 (22.09 to 41.55)18.18 (6.79 to 29.58)13.64 (3.50 to 23.78)
Week 3256.67 (46.43 to 66.90)34.09 (24.19 to 43.99)45.45 (30.74 to 60.17)31.82 (18.06 to 45.58)
Week 4052.22 (41.90 to 62.54)34.09 (24.19 to 43.99)50.00 (35.23 to 64.77)40.91 (26.38 to 55.44)
Week 5251.11 (40.78 to 61.44)26.14 (16.96 to 35.32)47.73 (32.97 to 62.49)29.55 (16.06 to 43.03)
SecondaryEuro Quality of Life 5 Dimensions (EQ-5D) - Utility Score Over Time Through Week 52

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a worse health state.

Time frame:
Baseline, Weeks 16, 32, 40, 52
Reported as:
Mean · units on a scale
Euro Quality of Life 5 Dimensions (EQ-5D) - Utility Score Over Time Through Week 52
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Baseline (n=90,88,44,44)0.784 ± 0.20880.797 ± 0.19910.779 ± 0.18030.741 ± 0.2183
Week 16 (n=84,83,38,39)0.957 ± 0.07780.930 ± 0.12260.905 ± 0.11910.817 ± 0.2108
Week 32 (n=83,82,38,37)0.955 ± 0.07960.904 ± 0.13680.960 ± 0.07390.917 ± 0.1477
Week 40 (n=81,81,37,36)0.950 ± 0.09400.918 ± 0.11770.954 ± 0.07760.938 ± 0.1125
Week 52 (n=80,78,35,36)0.938 ± 0.13030.893 ± 0.17190.941 ± 0.11180.887 ± 0.1626
SecondaryChange From Baseline in EQ-5D - Utility Score Over Time Through Week 52

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a worse health state.

Time frame:
Baseline and weeks 16, 32, 40, and 52
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D - Utility Score Over Time Through Week 52
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 16 (n=84,83,38,39)0.172 ± 0.21640.128 ± 0.21080.105 ± 0.18240.074 ± 0.2391
Week 32 (n=83,82,38,37)0.170 ± 0.20920.109 ± 0.23470.160 ± 0.19040.173 ± 0.2202
Week 40 (n=81,81,37,36)0.168 ± 0.21590.120 ± 0.23220.159 ± 0.19370.192 ± 0.2103
Week 52 (n=80,78,35,36)0.156 ± 0.20710.101 ± 0.24770.147 ± 0.21360.142 ± 0.2328
SecondaryEuro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) Over Time Through Week 52

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline and Weeks 16, 32, 40, and 52
Reported as:
Mean · units on a scale
Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) Over Time Through Week 52
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Baseline (n=90,88,44,44)65.8 ± 24.9069.5 ± 19.8466.4 ± 23.0967.4 ± 21.92
Week 16 (n=84,83,38,39)83.7 ± 15.3078.9 ± 15.4172.3 ± 22.0468.4 ± 20.20
Week 32 (n=83,82,38,37)84.5 ± 16.1782.4 ± 16.0085.2 ± 14.3681.7 ± 17.25
Week 40 (n=81,81,37,36)85.5 ± 14.4583.0 ± 14.3583.5 ± 16.8681.9 ± 16.03
Week 52 (n=80,78,35,36)82.5 ± 17.1380.0 ± 18.4085.0 ± 13.5880.7 ± 19.20
SecondaryChange From Baseline in EQ-5D - Visual Analog Scale (VAS) Over Time Through Week 52

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline and weeks 16, 32, 40, and 52
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D - Visual Analog Scale (VAS) Over Time Through Week 52
units on a scaleTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Week 16 (n=84,83,38,39)17.5 ± 25.238.8 ± 21.152.6 ± 22.17-0.6 ± 21.16
Week 32 (n=83,82,38,37)18.4 ± 25.9213.1 ± 22.3615.4 ± 23.5012.2 ± 23.99
Week 40 (n=81,81,37,36)19.9 ± 27.0713.3 ± 22.3114.3 ± 23.1911.8 ± 24.46
Week 52 (n=80,78,35,36)16.1 ± 26.089.9 ± 24.5415.2 ± 22.9610.7 ± 21.16
Other pre-specifiedTreatment-Emergent All Causalities Adverse Events (AEs) During Week 0-16

An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.

Time frame:
Baseline to Week 16
Reported as:
Number · participants
Treatment-Emergent All Causalities Adverse Events (AEs) During Week 0-16
participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo
Number of Participants with AEs(All Causalities)615743
Number of Participants with SAEs(All Causalities)020
Number of Participants Discontinued due to AEs133
Other pre-specifiedTreatment-Emergent All Causalities Adverse Events (AEs) During Week 0-52

An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.

Time frame:
Baseline to Week 52
Reported as:
Number · participants
Treatment-Emergent All Causalities Adverse Events (AEs) During Week 0-52
participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Number of Participants with AEs (All Causalities)76743533
Number of Participants with SAEs(All Causalities)2410
Number of Participants Discontinued due to AEs1331
Other pre-specifiedNumber of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-16

Study drugs were to be discontinued and the participant withdrawn for: 2 sequential absolute neutrophil counts (ANC) \<1.0 X 10\^9/L (1000/mm\^3); 2 sequential absolute lymphocyte counts \<0.5 X 10\^9/L; 2 sequential hemoglobin values \<9.0 g/dL and/or decreases of \>30% from baseline value; 2 sequential platelet counts \<75 X 10\^9/L; 2 sequential AST or ALT elevations ≥3X ULN with at least 1 total bilirubin value ≥2X ULN (reason #1); 2 sequential AST or ALT elevations ≥5X ULN regardless of total bilirubin or accompanying signs or symptoms (reason #2); 2 sequential increases in serum creatinine \>50% and an increase in serum creatinine \>0.5 mg/dL over the average of screening and baseline values; 2 sequential CK elevations \>10X ULN.

Time frame:
Baseline to Week 16
Reported as:
Number · participants
Number of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-16
participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo
2 Sequential absolute neutrophil count000
2 Sequential absolute lymphocyte count000
2 Sequential hemoglobin000
2 Sequential platelet count200
2 Sequential AST or ALT reason #1000
2 Sequential AST or ALT reason #2000
2 Sequential serum creatinine000
2 sequential creatine kinase000
Other pre-specifiedNumber of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-52

Study drugs were to be discontinued and the participant withdrawn for: 2 sequential absolute neutrophil counts (ANC) \<1.0 X 10\^9/L (1000/mm\^3); 2 sequential absolute lymphocyte counts \<0.5 X 10\^9/L; 2 sequential hemoglobin values \<9.0 g/dL and/or decreases of \>30% from baseline value; 2 sequential platelet counts \<75 X 10\^9/L; 2 sequential AST or ALT elevations ≥3X ULN with at least 1 total bilirubin value ≥2X ULN (reason #1); 2 sequential AST or ALT elevations ≥5X ULN regardless of total bilirubin or accompanying signs or symptoms (reason #2); 2 sequential increases in serum creatinine \>50% and an increase in serum creatinine \>0.5 mg/dL over the average of screening and baseline values; 2 sequential CK elevations \>10X ULN.

Time frame:
Baseline up to Week 52
Reported as:
Number · participants
Number of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-52
participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
2 Sequential absolute neutrophil count0000
2 Sequential absolute lymphocyte count0000
2 Sequential hemoglobin1000
2 Sequential platelet count2001
2 Sequential AST or ALT reason #10000
2 Sequential AST or ALT reason #20100
2 Sequential serum creatinine0000
2 sequential creatine kinase0000
Other pre-specifiedNumber of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-16

Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: pulse rate less than (\<)40 or greater than (\>)120 beats per minute (bpm), heart rate less than (\<)40 or greater than (\>)120 bpm; sitting systolic blood pressure (SBP) of greater than or equal to (\>=)30 millimeters of mercury (mmHg) change from baseline or sitting SBP \<90 mmHg, sitting diastolic blood pressure (DBP) \>=20 mmHg change from baseline or sitting DBP \<50 mmHg.

Time frame:
Baseline to Week 16
Reported as:
Number · participants
Number of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-16
participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo
Sitting SBP <90 mmHg (n=87,88,86)100
Sitting DBP <50 mmHg (n=87,88,86)001
Heart Rate <40 or >120 bpm (n=73,74,68)000
Pulse Rate <40 or >120 bpm (n=84,85,82)000
Sitting SBP max Increase >=30 Hg(n=87,88,86)100
Sitting DBP max Increase >=20 mmHg(n=87,88,86)011
Sitting SBP max Decrease >=30 mmHg(n=87,88,86)322
Sitting DBP max Decrease >=20 mmHg(n=87,88,86)251
Other pre-specifiedNumber of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-52

Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: pulse rate less than (\<)40 or greater than (\>)120 beats per minute (bpm), heart rate less than (\<)40 or greater than (\>)120 bpm; sitting systolic blood pressure (SBP) of greater than or equal to (\>=)30 millimeters of mercury (mmHg) change from baseline or sitting SBP \<90 mmHg, sitting diastolic blood pressure (DBP) \>=20 mmHg change from baseline or sitting DBP \<50 mmHg.

Time frame:
Baseline to Week 52
Reported as:
Number · participants
Number of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-52
participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Sitting SBP <90 mmHg (n=87,88,44,42)1000
Sitting DBP <50 mmHg (n=87,88,44,42)0001
Heart Rate <40 or >120 bpm (n=74,75,35,34)0000
Pulse Rate <40 or >120 bpm (n=86,85,42,40)0000
Sitting SBP max Increase >=30 Hg(n=87,88,44,42)5112
Sitting DBP max Increase >=20 mmHg(n=87,88,44,42)5421
Sitting SBP max Decrease >=30 mmHg(n=87,88,44,42)4321
Sitting DBP max Decrease >=20 mmHg(n=87,88,44,42)3811
Other pre-specifiedIncidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-16

CV event categories included: cerebrovascular accident (CVA), coronary revascularization procedure (percutaneous transluminal coronary angioplasty \[PTCA\], percutaneous coronary intervention \[PCI\], coronary bypass grafting \[CABG\], heart failure, major adverse cardiac events (MACE), myocardial infarction (MI), new ischemic heart disease, peripheral vascular disease (first diagnosis). MACE included any MI, CVA (stroke or transient ischemic attack), or CV death.

Time frame:
Baseline to Week 16
Reported as:
Number · participants
Incidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-16
participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo
Cerebrovascular Accident000
Coronary Revascularization Procedure000
Heart Failure000
MACE000
Myocardial Infarction000
New Ischemic Heart Disease000
Peripheral Vascular Disease000
Non-CV Death010
Other pre-specifiedIncidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-52

CV event categories included: cerebrovascular accident (CVA), coronary revascularization procedure (percutaneous transluminal coronary angioplasty \[PTCA\], percutaneous coronary intervention \[PCI\], coronary bypass grafting \[CABG\], heart failure, major adverse cardiac events (MACE), myocardial infarction (MI), new ischemic heart disease, peripheral vascular disease (first diagnosis). MACE included any MI, CVA (stroke or transient ischemic attack), or CV death.

Time frame:
Baseline up to Week 52
Reported as:
Number · participants
Incidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-52
participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Cerebrovascular Accident0000
Coronary Revascularization Procedure0110
Heart Failure0000
MACE0000
Myocardial Infarction0000
New Ischemic Heart Disease0000
Peripheral Vascular Disease0000
Non-CV Death0100
Other pre-specifiedNumber of Participants With Adjudicated Malignancy Events Reported During Week 0-16

As part of AE monitoring, potential malignancy events were adjudicated and centrally reviewed by a safety committee.

Time frame:
Baseline to Week 16
Reported as:
Number · participants
Number of Participants With Adjudicated Malignancy Events Reported During Week 0-16
participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo
Number of Participants With Adjudicated Malignancy Events Reported During Week 0-16010
Other pre-specifiedNumber of Participants With Adjudicated Malignancy Events Reported During Week 0-52

As part of AE monitoring, potential malignancy events were adjudicated and centrally reviewed by a safety committee.

Time frame:
Baseline to Week 52
Reported as:
Number · participants
Number of Participants With Adjudicated Malignancy Events Reported During Week 0-52
participantsTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mg
Number of Participants With Adjudicated Malignancy Events Reported During Week 0-521100

Adverse events

Collected over Baseline up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 10 mg—2/90 (2.2%)59/90 (65.6%)
Tofacitinib 5 mg—4/88 (4.5%)60/88 (68.2%)
Placebo to Tofacitinib 10 mg—1/44 (2.3%)25/44 (56.8%)
Placebo to Tofacitinib 5 mg—0/44 (0%)31/44 (70.5%)
Placebo—0/88 (0%)23/88 (26.1%)
Most frequent serious events
Most frequent serious events
EventTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mgPlacebo
Arteriosclerosis coronary arteryCardiac disorders0/901/881/440/440/88
Urinary tract infectionInfections and infestations0/901/880/440/440/88
Lung adenocarcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/901/880/440/440/88
Ankle fractureInjury, poisoning and procedural complications0/901/880/440/440/88
BronchopneumoniaInfections and infestations1/900/880/440/440/88
Small cell lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/900/880/440/440/88
Most frequent other events
Showing 10 of 26
Most frequent other events
EventTofacitinib 10 mgTofacitinib 5 mgPlacebo to Tofacitinib 10 mgPlacebo to Tofacitinib 5 mgPlacebo
NasopharyngitisInfections and infestations11/9012/886/449/443/88
Upper respiratory tract infectionInfections and infestations11/9018/885/447/443/88
HyperlipidaemiaMetabolism and nutrition disorders15/9013/888/447/449/88
Blood cholesterol increasedInvestigations15/909/881/443/442/88
Blood triglycerides increasedInvestigations8/9011/884/442/442/88
CoughRespiratory, thoracic and mediastinal disorders6/904/885/445/445/88
Alanine aminotransferase increasedInvestigations9/904/880/443/440/88
Low density lipoprotein increasedInvestigations8/906/880/442/440/88
HypomenorrhoeaReproductive system and breast disorders0/232/230/140/120/26
Menstruation irregularReproductive system and breast disorders1/232/230/141/120/26

Baseline characteristics

The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo.

Age, Continuous
Age, Continuous(years)Tofacitinib 10 mgTofacitinib 5 mgPlaceboTotal
Mean41.0 ± 12.040.7 ± 11.341.7 ± 13.741.1 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 10 mgTofacitinib 5 mgPlaceboTotal
Female23232672
Male676562194
08

Study locations

24 sites
  • Dept. Of dermatology &STD, Beijing Friendship Hospital, Capital Medical University
    Xicheng District, Beijing 100050, China
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510120, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Hospital of Skin Diseases, Chinese Academy of Medical Sciences
    Nanjing, Jiangsu 210042, China
  • Department of Dermatology, The Second Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116027, China
  • Huashan Hospital, Fudan University/Dermatology Department
    Shanghai, Shanghai 200040, China
  • Shanghai Changhai Hospital, Dermatology Department
    Shanghai, Shanghai 200433, China
  • Dermatology Department, The First Affiliated Hospital, The Fourth Military Medical University
    Xi'an, Shanxi 710032, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610031, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University/Dermatology and STD Dept
    Hangzhou, Zhejiang 310003, China
  • The Second Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310009, China
  • Peking University First Hospital / The Department of Dermatology
    Beijing, 100034, China
  • Peking University People's Hospital/Dermatology Department
    Beijing, 100044, China
  • Beijing Hospital of the Ministry of Health/Department of Dermatology
    Beijing, 100730, China
  • Peking Union Medical College Hospital/Department of Dermatology
    Beijing, 100730, China
  • Tianjin Medical University General Hospital, Dermatological Department
    Tianjin, 300052, China
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
  • Department of Dermatology,Severance Hospital, Yonsei University Health System
    Seoul, 120-452, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • National Cheng-Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch
    Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Zhang J, Tsai TF, Lee MG, Zheng M, Wang G, Jin H, Gu J, Li R, Liu Q, Chen J, Tu C, Qi C, Zhu H, Ports WC, Crook T. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci. 2017 Oct;88(1):36-45. doi: 10.1016/j.jdermsci.2017.05.004. Epub 2017 May 16. PubMed 28558978 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Jul 2015, 19 months.

Results were first posted in Mar 2019, 3 years 8 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 19 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2013
First posted
Mar 21, 2013
StartActual
Dec 2013
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Mar 5, 2019
Last update
Apr 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01815424
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 21, 2013
Start date
Dec 2013
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Mar 5, 2019
Last update
Apr 16, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion